

GUIDELINES **OPEN ACCESS**

Rhinitis, Sinusitis, and Upper Airway Disease

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

Bernardo Sousa-Pinto^{1,2} | Jean Bousquet^{3,4,5}  | Rafael José Vieira^{1,2}  | Holger J. Schünemann^{4,6,7} | Torsten Zuberbier^{3,4,6}  | Antonio Bognanni^{6,7}  | Alkis Togias⁸ | Boleslaw Samolinski⁹ | Arunas Valiulis^{10,11} | Sian Williams¹² | Anna Bedbrook⁵ | Wienaczyslaw Czarlewski^{5,13} | Maria Jose Torres¹⁴  | Mohamed H. Shamji¹⁵  | Mário Morais-Almeida¹⁶  | G. Walter Canonica^{7,17}  | Leticia de las Vecillas¹⁸  | Mark S. Dykewicz¹⁹ | Cristina Jacomelli²⁰ | Ludger Klimek^{21,22}  | Lucas Leemann²³ | Olga Lourenço²⁴  | Yuliia Palamarchuk²⁵ | Nikolaos G. Papadopoulos²⁶  | Ana Margarida Pereira^{1,27,28} | Marine Savouré^{29,30,31}  | Sanna K. Toppila-Salmi^{32,33}  | Maria Teresa Ventura^{34,35} | Juan José Yepes-Nuñez^{36,37} | Alvaro A. Cruz³⁸  | Giorgio Ciprandi³⁹ | Bilun Gemicioglu⁴⁰ | Mattia Giovannini^{41,42}  | Brigita Gradauskienė⁴³ | Tuomas Jartti⁴⁴  | Miloš Jeseňák^{45,46,47}  | Piotr Kuna⁴⁸ | Violeta Kvedariene^{49,50} | Désirée E. Larenas-Linnemann⁵¹ | Amir HA Latiff⁵² | Youssef Mohammad^{53,54} | Ken Ohta⁵⁵ | Padukudru A. Mahesh⁵⁶ | Isabella Pali-Schöll⁵⁷ | Oliver Pfaar⁵⁸  | Frederico S. Regateiro^{59,60,61,62} | Nicolas Roche^{63,64,65} | Luís Taborda-Barata^{62,66} | Charlotte Suppli Ulrik^{67,68} | Marilyn Valentin Rostan⁶⁹ | Giovanni Viegi⁷⁰ | Luo Zhang⁷¹  | Tari Haahtela⁷²  | Ivan Cherrez-Ojeda^{73,74}  | Juan Carlos Ivancevich⁷⁵ | Nikolai Khaltayev⁷⁶ | Arzu Yorgancioglu⁷⁷  | Baharudin Abdullah⁷⁸ | Mona Al-Ahmad⁷⁹ | Maryam Ali Al-Nesf⁸⁰  | Rita Amara^{1,2,81,82}  | Julijana Asllani⁸³  | Karl-C Bergmann^{3,4} | Jonathan A. Bernstein⁸⁴  | Michael S. Blaiss⁸⁵ | Fulvio Baido^{86,87} | Paulo Camargos⁸⁸ | Pedro Carreiro-Martins^{89,90} | Thomas Casale⁹¹ | Lorenzo Cecchi⁹²  | Alessandro Fiocchi⁹³  | Antonio F. M. Giuliano⁹⁴  | George Christoff⁹⁵ | Ieva Cirule⁹⁶ | Jaime Correia de Sousa⁹⁷  | Elisio M. Costa⁹⁸ | Stefano Del Giacco⁹⁹  | Philippe Devillier¹⁰⁰ | Dejan Dokic¹⁰¹ | Elham Hosny¹⁰² | Tomohisa Iinuma¹⁰³  | Carla Irani¹⁰⁴ | Zhanat Ispayeva¹⁰⁵ | Kaja Julge¹⁰⁶ | Igor Kaidashev¹⁰⁷ | Kazi S. Bennoor¹⁰⁸ | Helga Kraxner¹⁰⁹ | Inger Kull^{110,111}  | Marek Kulus¹¹² | Maciej Kupczyk⁴⁸ | Andriy Kurchenko¹¹³  | Stefania La Grutta¹¹⁴ | Neven Miculinic¹¹⁵ | Lan Le Thi Tuyet¹¹⁶ | Michael Makris¹¹⁷ | Branislava Milenkovic¹¹⁸ | Sang Min Lee¹¹⁹  | Stephen Montefort¹²⁰ | Andre Moreira^{121,122,123} | Joaquim Mullol^{124,125} | Rachel Nadir^{65,126}  | Alla Nakonechna^{127,128} | Hugo E. Neffen¹²⁹ | Marek Niedozytko¹³⁰  | Dieudonné Nyembue¹³¹ | Robyn E. O'Hehir¹³²  | Ismail Ogulur¹³³ | Yoshitaka Okamoto^{134,135} | Heidi Olze¹³⁶ | Oscar Palomares¹³⁷  | Petr Panzner¹³⁸  | Vincenzo Patella^{139,140,141}  | Ruby Pawankar¹⁴²  | Constantinos Pitsios¹⁴³ | Todor A. Popov¹⁴⁴ | Francesca Puggioni¹⁴⁵ | Santiago Quirce¹⁸ | Agn  Ramonaite^{146,147} | Marysia Recto¹⁴⁸ | Maria Susana Repka-Ramirez¹⁴⁹  | Graham Roberts^{150,151,152}  | Karla Robles-Velasco^{73,74,153}  | Menachem Rottem^{154,155} | Marianella Salapatas¹⁵⁶ | Joaquin Sastre¹⁵⁷ | Nicola Scichilone¹⁵⁸ | Juan-Carlos Sisul¹⁵⁹ | Dirceu Sol ¹⁶⁰ | Manuel E. Soto-Martinez¹⁶¹ | Milan Sova¹⁶² | Pongsakorn Tantilipikorn¹⁶³ | Ana Todo-Bom¹⁶⁴ | Vladyslav Tsaryk¹¹³  | Ioanna Tsiglianni^{165,166} | Marilyn Urrutia-Pereira¹⁶⁷ | Erkka Valovirta¹⁶⁸ | Tuula Vasankari^{169,170} | Dana Wallace¹⁷¹ | De Yun Wang¹⁷²  | Margitta Worm¹⁷³  | Osman M. Yusuf¹⁷⁴ | Mihaela Zidarn^{175,176} | Sara Gil-Mata^{1,2} | Manuel Marques-Cruz^{1,2} | Bassam Mahboub^{177,178} | Ignacio J. Ansotegui¹⁷⁹ | Antonino Romano^{180,181} | Werner Aberer¹⁸² | Maria Cristina Artesani⁹³  | Elena Azzolini¹⁷ | Bruno Barreto¹⁸³ | Joan Bartra^{184,185}  | Sven Becker¹⁸⁶  | Bianca Beghe¹⁸⁷ | Attilio Boner¹⁸⁸ | Ewa Borowiack^{189,190} | Jacques Bouchard¹⁹¹ | Melisande Bourgoin-Heck^{192,193,194}  | Luisa Brussini^{195,196} | Roland Buhl¹⁹⁷ | Jos  Antonio Castillo-Vizuet ^{198,199} | Denis Charpin²⁰⁰ | Niels H. Chavannes^{201,202} | Marta Chelmińska²⁰³ | Lei Cheng²⁰⁴ | Ekaterine Chkhartishvili²⁰⁵ | Seong H. Cho²⁰⁶  | Herberto Jose Chong-Neto²⁰⁷ | Deepa Choudhury²⁰⁸ | Derek K. Chu^{6,209} | Cemal Cingi²¹⁰  | Enrico Compalati²¹¹ | Raquel Albuquerque Costa¹ | Olga Mariana Cunha²¹²  | Biljana Cvetkovski²¹³ | Victoria Cardona-Dahl^{214,215} | Gennaro D'Amato²¹⁶  | Janet Davies^{217,218} | Danilo Di Bona²¹⁹ | Sandra N. Gonzalez Diaz²²⁰  | Maria V. Dimou²⁶ | Maria Doulaptsi²²¹  |

Abbreviations: ARIA, allergic rhinitis and its impact on asthma; GRADE, grading of recommendations, assessment, development, and evaluation; INAH, intranasal antihistamines; INCS, intranasal corticosteroids.

Bernardo Sousa-Pinto and Jean Bousquet equally contributed to this work.

For affiliations refer to page 16.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Renato Ferreira-da-Silva^{1,2} | Radoslaw Gawlik²²² | Mario Calvo-Gil²²³ | Ozlem Goksel²²⁴  | Maximiliano R. Gómez²²⁵ | Maia Gotua²²⁶ | Christos Grigoreas²²⁷ | Ineta Grisle²²⁸ | Maria Antonieta Guzman²²⁹ | Rachel House Tan^{230,231} | Michael Hyland²³² | Despo Ierodiakonou²³³ | Aspasia Karavelia²³⁴ | Paul Keith²³⁵  | Marta Kisiel²³⁶ | Tanja Soklic Kosak²³⁷  | Mitja Kosnik^{238,239}  | Ilgim Vardaloglu Koyuncu²⁴⁰ | Vicky Kritikos^{241,242}  | Justyna Litynska^{189,190} | Carlo Lombardi²⁴³ | Gilles Louis^{244,245} | Matteo Martini^{246,247}  | Cem Meço^{248,249,250} | Eris Mesonjesi²⁵¹ | Florin Mihaltan²⁵² | Marcin Moniuszko²⁵³ | Robert N. Naclerio²⁵⁴ | Kari C. Nadeau²⁵⁵  | Sophia Neisinger^{3,4} | Markus Ollert^{256,257}  | Michal Ordak²⁵⁸  | Giovanni Paoletti^{7,145}  | Nhan Pham-Thi^{263,264,265} | Elena Parmelli^{17,260} | Edgar Arturo Perdomo-Flores²⁶¹ | José Miguel Fuentes Pérez²⁶²  | Philippe Rombaux²⁶⁶ | Emmanuel Prokopakis²²¹ | Inês Ribeiro-Vaz^{1,2} | Giovanni Rolla¹⁹⁵ | Jan Romantowski¹³⁰ | Philippe Rombaux²⁶⁶ | Philip W. Rouadi^{267,268}  | Maia Rukhadze²⁶⁹ | Dermot Ryan²⁷⁰  | Ewelina Sadowska^{189,190}  | Daiju Sakurai²⁷¹ | Laila Salameh²⁷² | Faradiba Serpa Sarquis²⁷³ | Elie Serrano²⁷⁴ | Jane Da Silva^{275,276} | Michael Soyka²⁷⁷  | Krzysztof Specjalski¹³⁰ | Vesna Tomic-Spiric^{278,279} | Katarina Stevanovic^{3,4}  | Abirami Subramaniam²⁸⁰  | Maria Do Ceu Teixeira^{281,282} | Tuuli Thomander^{1,283,284} | Martina Vachova^{285,286} | Marianne van Hage^{287,288,289}  | Pakit Vichyanond^{290,291} | Martin Wagenmann²⁹²  | Fanny Wai San Ko²⁹³ | Pascal Werminghaus²⁹⁴ | Paraskevi Vicky Xepapadaki²⁶ | Yi-Kui Xiang^{3,4,295}  | Quintai Yang²⁹⁶ | Daniela Rivero Yeverino²⁹⁷ | Jaron Zuberbier¹³⁶ | João A. Fonseca^{1,2}

Correspondence: Jean Bousquet (jean.bousquet@orange.fr)

Received: 2 August 2025 | **Revised:** 5 September 2025 | **Accepted:** 21 September 2025

Funding: The work of this study has been funded within the context of the Allergic Rhinitis and its Impact on Asthma (ARIA) group.

Keywords: allergic rhinitis | guidelines | intranasal antihistamines | intranasal corticosteroids

ABSTRACT

Background: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024–2025). This manuscript presents the ARIA 2024–2025 recommendations for intranasal treatments, one of the mainstays for AR management.

Methods: The ARIA 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs.

Results: Eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications—most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants—or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH.

Conclusion: This ARIA 2024–2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.

1 | Introduction

Allergic rhinitis (AR) is a common chronic disease [1, 2] that substantially impacts quality of life, work and school productivity, and social activities [3–5]. Several guidelines have been produced for AR management. In particular, the Allergic Rhinitis and its Impact on Asthma (ARIA) group first proposed its guidelines for AR and asthma multimorbidity in 2001 [6]. Subsequent revisions were published in 2008 [7], 2010 [8], 2016 [9], and 2020 [10], reflecting the development of new therapeutic options and/or improvements in its methodology. The ARIA 2010 and 2016 updates were developed following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach [9].

Further advances in the evidence landscape have motivated the development of a 2024–2025 revision of the ARIA guidelines (ARIA 2024–2025). In particular, over the last years, evidence from mHealth data has shed light on medication use patterns and adherence [11, 12], patients' satisfaction with treatments [13], and the impact of AR on work productivity [3].

Considering the above, ARIA 2024–2025 guidelines have been conceived as person-centered, digitally enabled, and assisted by artificial intelligence (AI), using the GRADE approach [14]. This emphasis on a person-centered guideline is relevant due to inter-individual variability in (i) exposure and responses to triggers/allergens, (ii) impact of AR on daily life, (iii) values and preferences in relation to rhinitis health states,

and (iv) disease management (ranging from self-management to treatment by specialists).

This paper presents the first set of recommendations of ARIA 2024–2025, namely those on intranasal treatments for AR. Most guideline questions addressed in this paper concern intranasal corticosteroids (INCS), intranasal H₁-antihistamines (INAH) and fixed combinations of INAH+INCS. The target audience of these guidelines includes health professionals managing adults or children with AR, patients with AR, and health policymakers. ARIA 2024–2025 is supported by the European Academy of Allergy and Clinical Immunology (EAACI).

2 | Questions Addressed by This Guideline

In ARIA 2024–2025, 42 questions on AR management were voted by guideline panel members as “prioritized questions” [15]. Among these, 11 concerned exclusively intranasal AR treatments and are addressed by this paper. The full set of questions is listed in Table 1, alongside their corresponding recommendations and capsule justifications.

3 | Methodology

A full description of the methods used to develop recommendations in these guidelines is available elsewhere (Bousquet et al., under review). Here, we provide a brief methodological description to facilitate the interpretation of the guidelines.

3.1 | Questions and Outcomes of Interest

In ARIA 2024–2025, four approaches were used for the development of guideline clinical questions, including (i) identification of questions answered by previous ARIA guidelines and US Practice Parameters, (ii) surveying of ARIA panel members (healthcare professional-centered questions), (iii) identification of questions resulting from MASK-air studies, and (iv) use of AI to support the generation of guideline questions [15] (patient-centered questions). Questions were then subject to the GRADE formal process of prioritization [16] using GRADEpro [17].

Each question was assessed by considering the following set of outcomes (prioritized using GRADE formal processes [16]): nasal symptoms, ocular symptoms, quality of life, total symptoms, serious adverse events, and occurrence of any adverse event. Therefore, efficacy outcomes were nasal, ocular and total symptoms, as well as quality of life. Safety outcomes include any/total adverse events and serious adverse events.

3.2 | Evidence Review and Development of Recommendations

For each question, we gathered evidence on the different criteria of the evidence-to-decision (EtD) framework, a systematic and transparent approach that aims to support the formulation of recommendations [18, 19]. The EtD comprises 12 criteria: priority, desirable and undesirable effects, certainty of evidence,

values and preferences, balance of effects, resources required (and corresponding certainty of evidence), cost-effectiveness, equity, acceptability, and feasibility. In addition, the ARIA 2024–2025 guidelines included a 13th criterion—planetary health [20, 21]—to account for the effects of interventions on both human health and the health of the planet.

Evidence on desirable and undesirable effects was obtained by conducting four systematic reviews (SRs) of randomized controlled trials (RCTs): (i) comparison of intranasal medications versus placebo in adults [22–24], (ii) comparisons among intranasal medications in adults [25, 26], (iii) comparisons among intranasal medications in children [27], and (iv) comparison of nonfixed treatment combinations in adults and children (in preparation). In addition, evidence on undesirable effects was complemented by an analysis of pharmacovigilance data. In particular, we queried Vigibase, the World Health Organization (WHO) global database of adverse event reports for medicines and vaccines [28].

For values and preferences, we conducted a SR of the literature [29]. For the remaining criteria, we performed nonsystematic evidence reviews, which were complemented by evidence from other sources. In particular, we have conducted a survey of ARIA experts assessing the availability and costs of different AR medications (in preparation). Furthermore, we analyzed MASK-air direct patient data to obtain information on treatment acceptability (in particular, adherence, satisfaction, and use of co-medication) and indirect costs associated with productivity losses. The WHO List of Essential Medicines was consulted to inform judgments on equity [30].

The voting members of the ARIA 2024–2025 panel (i.e., members without conflicts of interest) convened at recurrent online meetings (average of two meetings per PICO question, with 3–4 PICO questions being discussed per meeting), where they issued a judgment for each criterion of each question through GRADEpro PanelVoice [17]. Based on all the provided judgments, the panel issued a recommendation for the respective guideline question. Recommendations were worded following the GRADE working group guidance (see “How to use these guidelines” section) [31]. In addition, for each recommendation, we present (i) considerations for preschool and school-aged children and adolescents (and, if evidence is available, other special populations, such as patients with asthma), and (ii) implementation considerations. The latter include, among others, aspects related to the application of recommendations in low- and middle-income countries, or to concerns with specific adverse events.

For both judgments and recommendations, we sought consensus among voting members of the guideline panel. If consensus was not reached, a formal voting process was set. The final form of guideline recommendations and their wording, as well as the final guideline document, has been reviewed and approved by all panel members.

4 | How to Use These Guidelines

The ARIA 2024–2025 guidelines are not intended to impose a standard of care for individual countries. They provide the basis

TABLE 1 | Recommendations of the ARIA 2024–2025 guidelines for the prioritized questions on intranasal treatments.

Recommendation	Capsule justification	Subgroup considerations	Implementation considerations
(A) New questions in ARIA 2024–2025			
Should a combination of an INAH+INCS vs. no treatment be used for the treatment of AR?			
In patients with AR in whom monotherapy is unlikely to lead to significant improvement in symptoms, we recommend using INAH+INCS over no treatment (strong recommendation/moderate CoE for seasonal AR and very low CoE for perennial AR)	INAH+INCS are effective in improving nasal symptoms, ocular symptoms and quality-of-life. INAH+INCS are overall safe, tententiously cost-effective and well accepted by patients	Recommendation applicable to children and adolescents	None specific
Should any specific INCS vs. other INCS be used for the treatment of AR?			
In patients with AR, we suggest using specific INCS (in particular, fluticasone furoate or fluticasone propionate) over others namely beclomethasone, budesonide, ciclesonide, mometasone and triamcinolone (conditional recommendation/low-very low CoE)	Fluticasone furoate and fluticasone propionate are the most effective INCS in improving nasal symptoms and quality of life in patients with seasonal AR. Individual INCS display a similar safety and satisfaction profile. Costs vary across countries	In children and adolescents, evidence was not sufficient to support a specific recommendation	In low- and middle-income countries, other INCS may be preferred based on local availability and affordability (budesonide is on the WHO List of Essential Medicines). From a planetary health perspective, locally produced generics may be preferable.
Should any specific combination of an INAH+INCS vs. other combination of an INAH+INCS be used for the treatment of AR?			
In patients with AR, we suggest using azelastine-fluticasone over olopatadine-mometasone (conditional recommendation/moderate CoE)	Azelastine-fluticasone is the most effective INAH+INCS in improving ocular symptoms and quality of life in patients with seasonal AR. Both INAH+INCS display a similar safety profile	In children and adolescents, we suggest either using azelastine-fluticasone or olopatadine-mometasone	In patients experiencing bitter taste with azelastine-fluticasone, olopatadine-mometasone may be preferred
Should a combination of an INCS and an intranasal decongestant vs. an INCS alone be used for the treatment of AR?			
In patients with AR, we suggest against using a combination of an INCS and an intranasal decongestant over an INCS alone (conditional recommendation/very low CoE)	Adding an intranasal decongestant to an INCS does not result in an increase in efficacy but is associated with a higher risk of adverse events, costs and impact on planetary health	Recommendation applicable to children and adolescents	In some specific situations, using intranasal decongestants for a short period of time when INCS are being introduced can be considered
(B) Questions with changed recommendation in terms of strength or directionality (compared to ARIA 2010/2016)			
Should an INAH vs. no treatment be used for the treatment of AR?			
In patients with AR, we recommend using INAH over no treatment (strong recommendation/moderate CoE)	INAH are effective in improving nasal symptoms, ocular symptoms and quality-of-life. INAH are overall safe, cost-effective and moderately accepted by patients	Recommendation applicable to children and adolescents	None specific

(Continues)

TABLE 1 | (Continued)

Recommendation	Capsule justification	Subgroup considerations	Implementation considerations
Should an intranasal decongestant vs. no treatment be used for the treatment of AR?			
In adolescents and adults with AR, we suggest against using intranasal decongestants in the long term (longer than 5 days) over no treatment (conditional recommendation very low CoE)	Decongestants display a trivial effect on nasal and ocular symptoms and are associated with an increased risk of adverse events	In pregnant women, children and the elderly, we suggest against using intranasal decongestants.	Recommendation concerning oxymetazoline, xylometazoline and tramazoline. The ARIA panel recommends against the use of ephedrine-based decongestants
Should a combination of an INAH+INCS vs. an INCS alone be used for the treatment of AR?			
In patients with AR, we suggest using a combination of an INAH+INCS over an INCS alone (conditional recommendation moderate CoE for seasonal AR and very low CoE for perennial AR)	INAH+INCS and INCS display a similar efficacy and safety profile. INAH+INCS are frequently cost-effective and typically associated with a faster onset of action and higher satisfaction	Recommendation applicable to children and adolescents	INAH+INCS may be particularly favored in patients with more severe symptoms. In low-income countries or low-resource settings, INCS may be preferred
(C) Other questions in ARIA 2024–2025			
Should an INCS vs. no treatment be used for the treatment of AR?			
In patients with AR, we recommend using INCS over no treatment (strong recommendation moderate CoE)	INCS are effective in improving nasal symptoms, ocular symptoms and quality-of-life. INCS are overall safe, cost-effective and well-accepted by patients	Recommendation applicable to children and adolescents	None specific
Should an INCS vs. an INAH be used for the treatment of AR?			
In patients with AR, we suggest using INCS over INAH (conditional recommendation moderate CoE)	INCS and INAH display a similar efficacy and safety profile. INCS are typically less expensive (and/or cost-effective) and associated with higher adherence and satisfaction	Recommendation applicable to children and adolescents	INCS may be particularly recommended for patients having taste alterations when using INAH. For patients with corticosteroid-phobia, epistaxis or glaucoma, or having poor medication adherence, INAH may be considered
Should a combination of an INAH+INCS vs. an INAH alone be used for the treatment of AR?			
In patients with AR, we suggest using a combination of an INAH+INCS over an INAH alone (conditional recommendation moderate CoE for seasonal AR and very low CoE for perennial AR)	INAH+INCS are more effective in improving nasal symptoms and quality of life. INAH+INCS display a similar safety profile. INAH+INCS tend to be cost-effective and are associated with higher adherence and satisfaction	Recommendation applicable to children and adolescents, even though evidence is scarcer	None specific

(Continues)

TABLE 1 | (Continued)

Recommendation	Capsule justification	Subgroup considerations	Implementation considerations
Should an INAH vs. an intranasal cromone be used for the treatment of AR?			
In patients with AR, we suggest using INAH over intranasal cromones (conditional recommendation/very low CoE)	INAH appear to be more effective in improving nasal and ocular symptoms, and are associated with higher satisfaction. INAH and intranasal cromones display a similar safety profile	Recommendation applicable to children and adolescents	None specific

Abbreviations: AR, allergic rhinitis; CoE, certainty of evidence; INAH, intranasal antihistamines; INCS, intranasal corticosteroids.

for rational, informed decisions, so that their recommendations do not correspond to dictates. Recommendations provide guidance for typical patients but cannot account for all unique individual circumstances. Thus, clinicians are encouraged to tailor their practice considering the clinical presentation of each patient and the specificities of the respective local context, and to reach decisions via shared decision-making.

For each question, in accordance with GRADE, we issued either a “strong” or “conditional” recommendation. The fact that a recommendation is “strong” or “conditional” reflects the panel’s confidence that following it would result in a more beneficial outcome for patients and other interest-holder categories (terminological clarification in Box 1). The wording of the recommendations reflects their strength, with “we recommend” implying a strong recommendation and “we suggest” implying a conditional recommendation. In each recommendation, we present information on the certainty of evidence across the different outcomes of interest (quality of the whole body of evidence, considering altogether desirable and undesirable effects; Box 1).

This manuscript provides a brief summary of the evidence underlying each recommendation (“brief justification”). Full EtDs for each question can be found online through links provided alongside each question.

Importantly, when summarizing our results on desirable and undesirable effects (“efficacy and safety”), we frequently report on the probability of differences between interventions being nontrivial (i.e., with corresponding effect sizes being sufficiently large that they are considered clinically important; Box 1 for terminological clarification).

5 | Recommendations and Summary of Findings

Table 1 lists the recommendations for each prioritized question. Below, we discuss, for each question, the rationale underlying each recommendation; we first present questions that are new in relation to ARIA 2010/2016, followed by those for which the strength or directionality of recommendations has changed, and finally by the remainder. Of note, we do not specifically refer to patients’ values and preferences in individual questions, as the same findings for values and preferences are applicable to all questions. In particular, we observed that patients generally (i) value the efficacy of interventions more over their safety, and (ii) consider nasal symptoms as those with the highest impact [29]. Table 2 presents, for each question, the judgment of the effect size and the certainty of the evidence for each outcome.

5.1 | New Questions in ARIA 2024–2025

5.1.1 | Should a Combination of an Intranasal H₁-Antihistamine and an Intranasal Corticosteroid vs. no Treatment Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/01/.

BOX 1 | Clarification of the terminology used in these guidelines.

Strength of recommendations

- Strong recommendation
 - *For patients:* Most patients in this situation would want the recommended course of action, and only a small proportion would not.
 - *For clinicians:* Most patients should receive the intervention. Adherence to a strong recommendation could be used as a quality criterion or performance indicator. Formal decision aids are not likely to be needed to help patients make decisions consistent with their values and preferences.
 - *For health care policy makers:* The recommendation can be adopted as a policy or performance measure in most situations.
- Conditional recommendation
 - *For patients:* Most patients in this situation would want the suggested course of action, but many would not.
 - *For clinicians:* Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids might be useful in helping patients to make decisions consistent with their values and preferences.
 - *For health care policy makers:* Policy making will require substantial debate and involvement of various stakeholders. Documentation of appropriate (e.g., shared) decision-making processes can serve as a performance measure.

Certainty of evidence: The certainty of evidence concerns how certain we are that the observed magnitude of desirable and undesirable anticipated effects lies on one side of a specified threshold or within a chosen range (reflecting the “quality” of available evidence). The certainty of evidence can be classified as “very low”, “low”, “moderate” or “high”. The certainty of evidence is independent of the directionality of the recommendation and of the effect sizes of the associations.

Categorization of the effect sizes: The magnitude of the anticipated desirable and undesirable effects (“benefits and harms”) is classified by the GRADE working group as “trivial or none”, “small”, “moderate” or “large”. A trivial effect is observed when the magnitude of the effects is so small that it is not sufficiently important in terms of anticipated health consequences. Nontrivial effects can be considered “small”, “moderate” or “large” depending on the magnitude of effect sizes.

Context: Fixed combinations of INAH+INCS are one of the mainstays for the treatment of AR, combining some of the advantages of INCS with those of INAH. However, INAH+INCS may not be affordable in all countries.

Recommendation: In patients with AR in whom monotherapy is unlikely to lead to significant improvement in symptoms, we

recommend using INAH+INCS over no treatment. (Strong recommendation based on moderate certainty of evidence for seasonal AR and very low certainty of evidence for perennial AR).

- Considerations in children and adolescents: The recommendation is applicable to children and adolescents, with available studies having assessed children aged as low as 4 years old.
- Implementation considerations: None specific.

Brief justification: See online supplement.

5.1.2 | Should Any Specific Intranasal Corticosteroid vs. Another Intranasal Corticosteroid Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/02/.

Context: There are several INCS available, rendering it important not only to provide recommendations at a class level but also on what may be the most indicated individual INCS.

Recommendation: In adult patients with AR, we suggest using specific INCS (in particular, fluticasone furoate or fluticasone propionate) over others (namely, beclomethasone, budesonide, ciclesonide, mometasone and triamcinolone). (Conditional recommendation based on very low or low certainty of evidence for most comparisons).

- **Considerations in children and adolescents:** In children and adolescents, evidence was not sufficient to support recommending a specific INCS (insufficient number of primary studies). Daily doses in children aged < 12 years old may be lower (e.g., half) of those used in adults.
- **Implementation considerations:** In low- and middle-income countries, other specific INCS may be preferred based on local availability and affordability (e.g., budesonide is on the WHO List of Essential Medicines). From a planetary health perspective, locally produced generics may be preferable.

5.1.2.1 | Brief Justification.

- Efficacy and safety:
 - A network meta-analysis suggested that, in seasonal AR, fluticasone furoate and fluticasone propionate were the INCS displaying the highest probability of being more effective in improving nasal symptoms. In perennial AR, budesonide was the INCS displaying the highest probability of being the most effective in improving nasal symptoms, but it was only assessed by one trial.
 - In seasonal AR, beclomethasone and fluticasone furoate were the INCS having the highest probability of being the most effective in improving ocular symptoms. In perennial AR, fluticasone furoate was the most effective INCS for ocular symptoms.

TABLE 2 | Judgments on the effect sizes and certainty of evidence (CoE) assessments for each outcome in each prioritized question comparing each intervention to a comparator.

Question	Seasonal allergic rhinitis						Perennial allergic rhinitis					
	Nasal symptoms	Ocular symptoms	Quality of life	AE	Serious AE	Nasal symptoms	Ocular symptoms	Quality of life	AE	Serious AE		
Should a combination of an INAH+INCS vs. no treatment be used for the treatment of AR?	Moderate	Small	Moderate	Trivial	Trivial	Small	— ^b	Small	Trivial	Trivial		
	Moderate	Moderate	Moderate	Moderate	Moderate	Very low	— ^b	Very low	Very low	Very low		
Should any specific INCS vs. other INCS be used for the treatment of AR?	Small	Trivial	Small	Trivial	Trivial	Trivial	Trivial	Small	Trivial	Trivial		
	Very low/Low ^a	Very low/Low ^a	Very low/Low ^a	Very low/Low ^a	Very low/Low ^a	Very low/Low ^a	Very low	Very low/Low ^a	Very low/Low ^a	Very low/Low ^a		
Should any specific combination of an INAH+INCS vs. other specific combination of an INAH+INCS be used for the treatment of AR?	Trivial	Small	Small	Trivial	Trivial	— ^b	— ^b	— ^b	— ^b	— ^b		
	Moderate	Moderate	Moderate	Moderate	Moderate	— ^b	— ^b	— ^b	— ^b	— ^b		
Should a combination of an INCS and an intranasal decongestant vs. an INCS alone be used for the treatment of AR?	Trivial	— ^b	Trivial	Small	Trivial	Trivial	— ^b	Trivial	Trivial	Trivial		
	Very low	— ^b	Low	Very low	Very low	Very low	— ^b	Very low	very low	Very low		
Should an INAH vs. no treatment be used for the treatment of AR?	Small	Small	Small	Trivial	Trivial	Small	— ^b	Small	Trivial	Trivial		
	Moderate	High	High	Low	Low	High	— ^b	High	Moderate	Moderate		
Should an intranasal decongestant vs. no treatment be used for the treatment of AR?	Trivial	— ^b	Trivial	Trivial	— ^b	Trivial	— ^b	Trivial	Small	— ^b		
	Very low	— ^b	Low	Moderate	— ^b	Low	— ^b	Very low	Low	— ^b		

(Continues)

TABLE 2 | (Continued)

Question	Seasonal allergic rhinitis					Perennial allergic rhinitis				
	Nasal symptoms	Ocular symptoms	Quality of life	AE	Serious AE	Nasal symptoms	Ocular symptoms	Quality of life	AE	Serious AE
Should a combination of an INAH+INCS vs. an INCS alone be used for the treatment of AR?	Trivial	Trivial	Trivial	Trivial	Trivial	Trivial	— ^b	Trivial	Trivial	Trivial
	Moderate	High	High	Moderate	Moderate	Very low	— ^b	Very low	Very low	Very low
Should an INCS vs. no treatment be used for the treatment of AR?	Small	Small	Small	Trivial	Trivial	Small	Small	Small	Trivial	Trivial
	Moderate	High	Moderate	Moderate	Moderate	High	Moderate	Moderate	Moderate	Moderate
Should an INCS vs. an INAH be used for the treatment of AR?	Trivial	Trivial	Trivial	Trivial	Trivial	Trivial	— ^b	Trivial	Trivial	Trivial
	Low	Moderate	High	Moderate	Moderate	High	— ^b	Low	Moderate	Moderate
Should a combination of an INAH+INCS vs. an INAH alone be used for the treatment of AR?	Trivial	Trivial	Small	Trivial	Trivial	Small	— ^b	Trivial	Trivial	Trivial
	High	Moderate	High	Moderate	Moderate	Very low	— ^b	Very low	Moderate	Moderate
Should an INAH vs. an intranasal cromone be used for the treatment of AR?	Small	Small	— ^b	Trivial	— ^b	— ^b	— ^b	— ^b	— ^b	— ^b
	Very low	Very low	— ^b	Very low	— ^b	— ^b	— ^b	— ^b	— ^b	— ^b

Abbreviations: AE, adverse events; AR, allergic rhinitis; INAH, intranasal antihistamines; INCS, intranasal corticosteroids. Colour code: Effect size: The darker the blue the larger the effect size. CoE: Green=High, Yellow=Moderate, Orange=Low, Red=Very low.

^aMost common CoE assessments for the considered comparisons.

^bNo available evidence.

- In terms of rhinoconjunctivitis-related quality of life (RQLQ), fluticasone furoate and fluticasone propionate were the INCS displaying the highest probability of being the most effective in seasonal AR. In perennial AR, the most effective INCS were fluticasone furoate and beclomethasone.
- Similar frequencies and patterns of adverse events and serious adverse events were observed with the different INCS based on data from RCTs and pharmacovigilance.
- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested that the least and most expensive INCS vary widely across countries. We did not identify any cost-effectiveness study comparing INCS, but MASK-air data suggests that mometasone and budesonide tend to be more frequently cost-effective interventions compared to other INCS. Budesonide is the only INCS on the WHO List of Essential Medicines.
- **Acceptability and feasibility:** MASK-air data suggest that fluticasone furoate and mometasone are the INCS associated with higher adherence. The different INCS are associated with similar levels of treatment satisfaction. However, fluticasone furoate and fluticasone propionate seem to be used more often in co-medication than other individual INCS.
- **Planetary health:** No specific evidence was found in terms of comparative impact on planetary health.

5.1.3 | Should Any Specific Combination of an Intranasal H₁-Antihistamine and an Intranasal Corticosteroid vs. Another Combination of an Intranasal H₁-Antihistamine and an Intranasal Corticosteroid Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/03/.

Context: There are two widely used INAH+INCS—azelastine-fluticasone and olopatadine-mometasone, rendering it important not only to provide recommendations at a class level but also on what may be the most indicated individual INAH+INCS.

Recommendation: In adult patients with AR, we suggest using azelastine-fluticasone over olopatadine-mometasone. (Conditional recommendation based on moderate certainty of evidence for seasonal AR).

- **Considerations in children and adolescents:** In children and adolescents, we suggest either using azelastine-fluticasone or olopatadine-mometasone based on the available scarce evidence.
- **Implementation considerations:** In patients experiencing bitter taste with azelastine-fluticasone, olopatadine-mometasone may be preferred.

5.1.3.1 | Brief Justification.

- **Efficacy and safety:**
 - A network meta-analysis suggested that, compared to olopatadine-mometasone, azelastine-fluticasone is

associated with a 23% probability of resulting in a non-trivial improvement in nasal symptoms in seasonal AR. For ocular symptoms and RQLQ, this probability was 56%.

- For perennial AR, no evidence was available for the comparison between azelastine-fluticasone versus olopatadine-mometasone.
- Similar frequencies of adverse events were observed with azelastine-fluticasone and olopatadine-mometasone (trivial difference). Serious adverse events associated with these interventions are rare and most of those reported in RCTs have been judged unlikely to be related to the treatment.
- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested olopatadine-mometasone to be more expensive than azelastine-fluticasone in 8 out of 14 countries for which data were available. We did not identify any cost-effectiveness study comparing these two medications. Neither azelastine-fluticasone nor olopatadine-mometasone are on the WHO List of Essential Medicines, but azelastine-fluticasone seems to be available in a wider number of countries.
- **Acceptability and feasibility:** MASK-air data suggest that azelastine-fluticasone is associated with higher adherence and treatment satisfaction. However, azelastine-fluticasone is associated with higher odds of being used in co-medication (a proxy of poor rhinitis control) than olopatadine-mometasone. In addition, there are studies on sensory attributes that favor olopatadine-mometasone. Both azelastine-fluticasone and olopatadine-mometasone display a fast onset of action.

Planetary health: No specific evidence was found in terms of comparative impact on planetary health. Both branded products are manufactured in Asia, with olopatadine-mometasone being distributed in a plastic vial and azelastine-fluticasone being distributed in a glass vial.

5.1.4 | Should a Combination of an Intranasal Corticosteroid and an Intranasal Decongestant vs. an Intranasal Corticosteroid Alone Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/04/.

Context: Patients with AR using INCS often do co-medication with intranasal decongestants (oxymetazoline, xylometazoline or tramazoline), particularly as the latter have a rapid onset and may help relieve nasal congestion.

Recommendation: In patients with AR, we suggest against using a combination of an INCS + intranasal decongestant over an INCS alone. (Conditional recommendation based on very low certainty of evidence).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents.

- **Implementation considerations:** This recommendation is particularly applicable to long-term treatment (longer than 5 days). In some specific situations using intranasal decongestants for a short period of time—less than 5 days—when INCS are being introduced (to “compensate” for the slow onset of action of INCS) can be considered. However, if available and affordable, this can also be achieved with INAH+INCS (e.g., patients who cannot be treated for a long period of time with INAH+INCS due to costs or intolerance to bitter taste can have INAH+INCS for few days—to achieve fast symptom relief—followed by INCS). The ARIA panel recommends against the use of ephedrine-based decongestants due to safety and legal concerns.

5.1.4.1 | Brief Justification.

- **Efficacy and safety**
 - Primary studies assessing nasal symptoms were too different to allow for estimating meta-analytical measures. However, these studies point to trivial differences when comparing the improvement of nasal symptoms between INCS + intranasal decongestants versus INCS alone.
 - For ocular symptoms, a single study indicated that “nonsignificant differences were identified for patients with seasonal AR” (no further information was provided).
 - Results from a network meta-analysis suggested that INCS + intranasal decongestants and INCS are associated with a similar improvement in RQLQ, both in seasonal AR and perennial AR (trivial differences).
 - INCS + decongestants were associated with increased risk of adverse events compared to INCS (small but important difference). Of note, the long-term use of decongestants has been linked to rhinitis medicamentosa. Serious adverse events associated with these interventions are rare and most of those reported in RCTs have been judged unlikely to be related to the treatment.
- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested INCS + intranasal decongestants to represent up to more \$200 per year than INCS alone for countries for which data were available. No cost-effectiveness studies have been identified comparing INCS + intranasal decongestants versus INCS alone. There is both an INCS (budesonide) and a decongestant (xylometazoline) on the WHO List of Essential Medicines.
- **Acceptability and feasibility:** MASK-air data suggest that INCS + decongestants are associated with lower adherence and treatment satisfaction. Intranasal decongestants display a faster onset of action than INCS.
- **Planetary health:** Considering that INCS + intranasal decongestants are not produced as fixed combinations, the additional use of intranasal decongestants implies the use of additional resources with environmental impact.

5.2 | Questions With a Change in Recommendation Directionality and/or Strength in ARIA 2024–2025

5.2.1 | Should an Intranasal H₁-Antihistamine vs. no Treatment Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/05/.

Context: INAH are one possible therapeutic option in patients with AR, being often considered for patients with corticosteroid phobia and displaying a fast onset of action.

Recommendation: In patients with AR, we recommend using INAH over no treatment. (Strong recommendation based on moderate certainty of evidence).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents.
- **Implementation considerations:** None specific.

Brief justification: See online supplement.

5.2.2 | Should an Intranasal Decongestant vs. no Treatment Be Used For the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/06/.

Context: Intranasal decongestants (oxymetazoline, xylometazoline and tramazoline) are frequently used by patients with AR, particularly considering that they are commonly sold over-the-counter and display a fast onset of action in nasal congestion.

Recommendation: In patients with AR, we suggest against using intranasal decongestants in the long term (longer than 5 days) over no treatment. (Conditional recommendation based on very low certainty of evidence).

- **Considerations in specific age groups and conditions:** For preschool and young school-aged children (<12 years), there should be avoidance of intranasal decongestants. There should also be avoidance of intranasal decongestants in pregnant women, especially in the first trimester, considering the potential teratogenic effects of nasal decongestants. Considering the risk of serious adverse events, the use of intranasal decongestants in the elderly is also discouraged.
- **Implementation considerations:** This recommendation concerns oxymetazoline, xylometazoline and tramazoline. The panel suggests that the use of intranasal decongestants should be restricted to short-term relief (not longer than 5 days and preferably shorter) of nasal congestion. The ARIA panel also recommends against the use of ephedrine-based decongestants due to safety and legal concerns.

Brief justification: See online supplement.

5.2.3 | Should a Combination of an Intranasal H₁-Antihistamine and an Intranasal Corticosteroid vs. an Intranasal Corticosteroid Alone Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/07/.

Context: INCS+INAH offer some advantages in relation to INCS in terms of onset of action and, potentially, effectiveness. However, INCS are more widely available and are more affordable.

Recommendation: In patients with AR, we suggest using a fixed combination of an INAH and INCS over an INCS alone. (Conditional recommendation based on moderate certainty of evidence for seasonal AR and on very low certainty of evidence for perennial AR).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents.
- **Implementation considerations:** Aspects such as adherence, baseline severity and history of medication use may be relevant to be considered. Fixed combinations of INAH+INCS may be particularly favored in patients with severe symptoms. In low-income countries or low-resource settings, INCS may be preferred.

5.2.3.1 | Brief Justification.

- **Efficacy and safety**
 - A network meta-analysis suggested that INAH+INCS and INCS are associated with a similar improvement in nasal and ocular symptoms, as well as in RQLQ, both in seasonal AR and perennial AR (trivial differences).
 - Similar frequencies of adverse events were observed with INAH+INCS and INCS (trivial difference). Serious adverse events associated with these interventions are rare and most of those reported in RCTs have been judged unlikely to be related to the treatment.
- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested INAH+INCS to be more expensive than INCS in 34 out of 36 countries for which data were available. However, INAH+INCS are likely cost-effective in most countries both when considering a willingness-to-pay of \$50,000/QALY gained or of one time the GDP per capita/QALY gained (the only exception may be some low- and middle-income countries). One INCS—budesonide—is on the WHO List of Essential Medicines, but the same does not occur with INAH+INCS.
- **Acceptability and feasibility:** MASK-air data suggest that INAH+INCS are associated with higher treatment satisfaction and with lower odds of being used in co-medication (a proxy of poor rhinitis control). In addition, INAH+INCS display a faster onset of action.

Planetary health: No specific evidence was found in terms of comparative impact on planetary health, even though it is possible that the production of two active compounds may have a higher environmental impact than the production of one.

5.3 | Other Questions Evaluated in ARIA 2024–2025

5.3.1 | Should an Intranasal Corticosteroid vs. no Treatment Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/08/.

Context: INCS are one of the mainstays of the treatment of AR, being widely available. Budesonide is listed in the WHO List of Essential Medicines.

Recommendation: In patients with AR, we recommend using INCS over no treatment. (Strong recommendation based on moderate certainty of evidence).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents.
- **Implementation considerations:** None specific.

Brief justification: See online supplement.

5.3.2 | Should an Intranasal Corticosteroid vs. an Intranasal H₁-Antihistamine Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/09/.

Context: INCS and INAH are two of the most commonly used classes for the treatment of AR. These two treatment classes have distinct profiles in terms of acceptability and affordability, among others.

Recommendation: In patients with AR, we suggest using INCS over INAH. (Conditional recommendation based on moderate certainty of evidence).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents.
- **Implementation considerations:** INCS may be particularly recommended for patients having taste alterations when using INAH. For patients with corticosteroid-phobia, epistaxis secondary to INCS or glaucoma, or having poor medication adherence, INAH may be the preferred intervention.

5.3.2.1 | Brief Justification.

- **Efficacy and safety**
 - A network meta-analysis suggested that, compared to INAH, INCS are associated with a trivial improvement in nasal symptoms and in RQLQ in seasonal and perennial AR.
 - For ocular symptoms, either differences between treatments were trivial (seasonal AR) or evidence was not found (perennial AR).
 - Similar frequencies of adverse events were observed with INCS and INAH (trivial difference). Serious adverse events associated with these interventions are rare and most of those reported in RCTs have been judged unlikely to be related to the treatment. Although rare,

pharmacovigilance data suggested glaucoma to be more frequent with INCS than INAH.

- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested INAH to be more expensive than INCS in 21 out of 29 countries for which data were available. In addition, in most countries where INCS are more expensive than INAH, INCS were found to be cost-effective when considering a willingness-to-pay of \$50,000/Quality Adjusted Life Years (QALY) gained or of one time the Gross Domestic Product (GDP) per capita/QALY gained. One INCS—budesonide—is on the WHO List of Essential Medicines, but the same does not occur with INAH. In addition, INCS are available in more countries than INAH.
- **Acceptability and feasibility:** MASK-air data suggest that INCS are associated with higher adherence and treatment satisfaction, as well as with lower odds of being used in co-medication (a proxy of poor rhinitis control). However, INAH display a faster onset of action.
- **Planetary health:** No specific evidence was found in terms of comparative impact on planetary health.

5.3.3 | Should a Combination of an Intranasal H₁-Antihistamine and an Intranasal Corticosteroid vs. an Intranasal H₁-Antihistamine Alone Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/10/.

Context: INCS+INAH have been proposed as the first-line treatment of AR by previous guidelines. However, some patients are corticosteroid-phobic or have glaucoma. Thus, INAH alone may be of interest.

Recommendation: In patients with AR, we suggest using a fixed combination of an INAH+INCS over an INAH alone. (Conditional recommendation based on moderate certainty of evidence for seasonal AR and on very low certainty of evidence for perennial AR).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents, even though evidence is scarcer (no studies on perennial AR and the only desirable outcome for which INAH+INCS are favored over INAH is rhinoconjunctivitis-related quality-of-life).
- **Implementation considerations:** None specific.

5.3.3.1 | Brief Justification.

- **Efficacy and safety**
 - A network meta-analysis suggested that, compared to INAH, INAH+INCS are associated with an improvement in nasal symptoms in seasonal and perennial AR (25% and 45% probability of nontrivial improvement in nasal symptoms, respectively).
 - For ocular symptoms, either differences between treatments were trivial (seasonal AR) or evidence was not found (perennial AR).

- INAH+INCS displayed a higher probability of resulting in a nontrivial improvement of RQLQ in patients with seasonal AR (83%) than in patients with perennial AR (16%).
- Similar frequencies of adverse events were observed with INAH+INCS and INAH (trivial difference). Serious adverse events associated with these interventions are rare and most of those reported in RCTs have been judged unlikely to be related to the treatment.

- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested INAH+INCS to be more expensive than INAH in 23 out of 27 countries for which data were available. However, INAH+INCS are likely cost-effective in most countries both when considering a willingness-to-pay of \$50,000/QALY gained or of one time the GDP per capita/QALY gained (the only exception may be some low-income countries). No INAH+INCS or INAH are on the WHO List of Essential Medicines.

- **Acceptability and feasibility:** MASK-air data suggest that INAH+INCS are associated with higher adherence and treatment satisfaction, as well as with lower odds of being used in co-medication (a proxy of poor rhinitis control). In addition, INAH+INCS seem to display a faster onset of action.

- **Planetary health:** No specific evidence was found in terms of comparative impact on planetary health, even though it is possible that the production of two active compounds may have a higher environmental impact than the production of one.

5.3.4 | Should an Intranasal H₁-Antihistamine vs. an Intranasal Chromone Be Used for the Treatment of AR?

Link for the full EtD: https://www.mask-air.com/etd_nasal/11/.

Context: INAH and intranasal chromones are two alternatives that are often used in AR patients, including those with corticosteroid-phobia or who desire a fast onset of action.

Recommendation: In patients with AR, we suggest using INAH over intranasal chromones. (Conditional recommendation based on very low certainty of evidence).

- **Considerations in children and adolescents:** The recommendation is applicable to children and adolescents.
- **Implementation considerations:** None specific.

5.3.4.1 | Brief Justification.

- **Efficacy and safety**
 - Existing evidence is scarce and contradictory but overall suggests that intranasal antihistamines are associated with trivial or small improvements in nasal and ocular symptoms when compared to intranasal chromones.
 - For RQLQ, no evidence was found.
 - Similar frequencies of adverse events were observed with INAH and intranasal chromones (trivial difference).

Serious adverse events associated with these interventions are rare and most of those reported in RCTs have been judged unlikely to be related to the treatment.

- **Resources required, cost-effectiveness and equity:** A survey of ARIA experts suggested INAH to be more expensive than intranasal cromones in 10 out of 16 countries for which data were available (intranasal cromones are not available in many countries). However, differences in costs tended to be small. We did not identify cost-effectiveness studies comparing INAH to intranasal cromones. No INAH or intranasal cromone is on the WHO List of Essential Medicines.
- **Acceptability and feasibility:** MASK-air data suggest that INAH and intranasal cromones (i) are used in co-medication at a similar frequency, and (ii) are associated with similar adherence. However, INAH are associated with higher treatment satisfaction.
- **Planetary health:** No specific evidence was found in terms of comparative impact on planetary health.

6 | Conclusions

Intranasal medications, in particular INCS, INAH and INAH+INCS, are part of the mainstay of AR treatment. In ARIA 2024–2025, we formulated recommendations on 11

questions concerning AR intranasal treatment. Overall, we suggest using INAH+INCS over INAH or INCS and INCS over INAH. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values and preferences and the affordability of treatment options.

Questions on intranasal treatments had been previously addressed in past editions of the ARIA guidelines. Box 2 and Table 3 compare recommendations on intranasal treatments of ARIA 2024–2025 *vis-à-vis* ARIA 2010/2016 guidelines. In brief, four questions were addressed in ARIA 2024–2025 for the first time, including questions comparing individual INCS and individual INAH+INCS. Among the remaining questions, a change in the strength and/or the directionality of recommendations was observed in three questions. For example, differently from the ARIA 2016 guidelines, we now suggest the use of INAH+INCS over INCS (particularly among patients with more severe symptoms). These changes reflect not only a larger amount of evidence from RCTs but also the evaluation of other evidence sources, such as mHealth data and results of a survey of ARIA experts. Considering these data sources was crucial to inform on criteria such as the acceptability and resources required for the interventions, rendering the guideline more person-centered. In addition, since these data reflect information from different countries—MASK-air is available in 30 countries, and the survey was answered by experts from more than 40 countries—their incorporation renders ARIA 2024–2025 more easily tailored to different contexts.

BOX 2 | Summary of what is new in the ARIA 2024–2025 guidelines in comparison to ARIA 2010–2016 guidelines.

New questions

- Should an INAH+INCS vs. no treatment be used for the treatment of AR?
 - Recommendation: “In patients with AR in whom monotherapy is unlikely to lead to significant improvement in symptoms, we recommend using INAH+INCS over no treatment. (Strong recommendation based on moderate certainty of evidence for seasonal AR and very low certainty of evidence for perennial AR)”
- Should any specific INCS vs. other INCS be used for the treatment of AR?
 - Recommendation: “In patients with AR, we suggest using specific INCS (in particular, fluticasone furoate or fluticasone propionate) over others (namely, beclomethasone, budesonide, ciclesonide, mometasone and triamcinolone). (Conditional recommendation based on very low or low certainty of evidence for most comparisons)”
- Should any specific INAH+INCS vs. other INAH+INCS be used for the treatment of AR?
 - Recommendation: “In patients with AR, we suggest using azelastine-fluticasone over olopatadine-mometasone. (Conditional recommendation based on moderate certainty of evidence for seasonal AR)”
- Should a combination of an INCS and an intranasal decongestant vs. an INCS alone be used for the treatment of AR?
 - Recommendation: “In patients with AR, we suggest against using a combination of an INCS + intranasal decongestant over an INCS alone. (Conditional recommendation based on very low certainty of evidence)”

Questions with changed recommendation (in terms of directionality or strength):

- Should an INAH vs. no treatment be used for the treatment of AR?
 - Recommendation changed from *conditional recommendation in favor of INAH* (2010/2016 guidelines) to a *strong recommendation in favor of INAH* (2024–2025 guidelines).
- Should an intranasal decongestant vs. no treatment be used for the treatment of AR?
 - Recommendation changed from *conditional recommendation in favor of intranasal decongestants* (2010/2016 guidelines) to a *conditional recommendation against the intervention* (2024–2025 guidelines).
- Should a combination of an INAH+INCS vs. an INCS alone be used for the treatment of AR?
 - Recommendation changed from *conditional recommendation either for either INAH + INCS or INCS* (2010/2016 guidelines) to a *conditional recommendation in favor of INAH + INCS* (2024–2025 guidelines).

AR, Allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; INAH, Intranasal H1-antihistamines; INAH+INCS, Fixed combinations of intranasal H1-antihistamines and intranasal corticosteroids; INCS, Intranasal corticosteroids.

TABLE 3 | Comparison of the recommendations on intranasal treatments of the ARIA 2024–2025 and of the ARIA 2010/2016 guidelines. Recommendations of the ARIA 2024–2025 guidelines are highlighted by a shade in a cell; recommendations of the ARIA 2010/2016 guidelines are highlighted by a border in a cell. Shade/border color code: Green = High certainty of evidence; Yellow = Moderate certainty of evidence; Orange = Low certainty of evidence; Red = Very low certainty of evidence.

Question	Disease	Recommendation				
Should a combination of an INAH+INCS vs no treatment be used for the treatment of AR?	PAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
	SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should any specific INCS vs. other INCS be used for the treatment of AR?	PAR/ SAR	Strong recommendation against specific interventions	Conditional recommendation against specific interventions	Conditional recommendation for either some specific interventions or comparisons	Conditional recommendation for specific interventions (FF or FP)	Strong recommendation for specific intervention
Should any specific combination if an INAH+INCS vs other specific combination of an INAH+INCS be used for the treatment of AR?	SAR ^a	Strong recommendation against [azelastine-fluticasone]	Conditional recommendation against [azelastine-fluticasone]	Conditional recommendation for either [azelastine-fluticasone or olopatadine-mometasone]	Conditional recommendation for [azelastine-fluticasone]	Strong recommendation for [azelastine-fluticasone]
Should a combination of an INCS and an intranasal decongestant vs. an INCS alone be used for the treatment of AR?	PAR/ SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should an INAH vs no treatment be used for the treatment of AR?	PAR/ SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should an intranasal decongestant vs. no treatment be used for the treatment of AR?	PAR/ SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should a combination of an INAH+INCS vs. an INCS alone be used for the treatment of AR?	PAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
	SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should an INCS vs no treatment be used for the treatment of AR?	PAR/ SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should an INCS vs. an INAH be used for the treatment of AR?	PAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
	SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should a combination of an INAH+INCS vs. an INAH alone be used for the treatment of AR?	PAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should an INAH vs. an intranasal chromone be used for the treatment of AR?	PAR/ SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
	PAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should a combination of an INAH+INCS vs. an INAH alone be used for the treatment of AR?	PAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
	SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
Should an INAH vs. an intranasal chromone be used for the treatment of AR?	PAR/ SAR	Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention

Abbreviations: AR, allergic rhinitis; FF, fluticasone furoate; FP, fluticasone propionate; INAH, intranasal antihistamines; INCS, intranasal corticosteroids; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.

^aNo evidence for PAR.

Despite the new evidence incorporated in ARIA 2024–2025, there are still some knowledge gaps that would merit further research. There is a relative lack of RCTs assessing specific subgroups of participants, including those with mild disease, those with comorbid asthma or conjunctivitis, patients from ethnic minorities, older people and—for some outcomes—children. In addition, differences in the effect of interventions by sex have not been explored. Cost-utility studies comparing different treatments in AR are also lacking and, for some questions, we were not able to perform or include any study addressing the cost-effectiveness criterion. Finally, there is insufficient evidence on the planetary health impact of AR interventions (with no life cycle assessment studies having been performed for such treatments), precluding this criterion from playing a decisive role in most recommendations.

Contrary to previous ARIA guidelines, we opted not to present separate recommendations for seasonal vs. perennial AR. This decision is grounded on (i) recent studies pointing to the higher relative importance of severity over disease duration [32, 33], and (ii) the fact that our SR and meta-analyses usually found an agreement between results observed for patients with seasonal and perennial AR [23, 25]. However, since the certainty of evidence was often different between seasonal and perennial AR, there were some recommendations for which we highlighted such differences. Of note, we referred to “perennial” or “seasonal AR” considering that most RCTs did not adopt the ARIA classification (which classifies AR as “persistent” or “intermittent” [6]).

Our recommendations assume a correct use of the different intranasal medications, with inadequate use potentially resulting in lower efficacy and safety concerns [34, 35] (a video teaching patients how to use intranasal sprays can be found at https://www.youtube.com/watch?v=_ytYjITLoJM). In addition, variations in treatment duration were not explored. Future documents of the ARIA 2024–2025 guidelines will address the question of whether patients should take medications chronically or on an as-needed basis.

These guidelines have limitations. For desirable and undesirable effects, evidence was mostly obtained from RCTs. While RCTs are the paradigm for assessing the efficacy of interventions, they tend to be associated with generalisability concerns (e.g., with overrepresentation of patients with more severe disease [36]). Also, there was a relative lack of evidence on the differential impact of AR medications in patients with and without asthma. Finally, there were several comparisons on intranasal treatments of AR that we did not assess, as the corresponding questions were not prioritized [15]. The evaluated interventions were all pharmacological in nature, but it is important to note that nonpharmacological intranasal interventions (e.g., nasal washes) are often done by patients with AR. Accordingly, the off-label use of products for AR was not evaluated in these guidelines.

There are also important strengths associated with ARIA 2024–2025. We have followed the GRADE approach, using EtDs to develop recommendations. Additionally, we have used several approaches to formulate guideline questions and considered different data sources. Finally, we have conducted several SR

and meta-analyses to provide updated evidence on the desirable and undesirable effects of interventions. These SR have been complemented by several other evidence sources (e.g., mHealth data, pharmacovigilance data and data from a survey of experts). These sources of data have an international scope, facilitating the tailoring of the ARIA guidelines to different regions or contexts.

In conclusion, this report compared intranasal treatments for the management of AR. The recommendations were developed following the GRADE approach and consider evidence from multiple sources, including systematic reviews of randomized controlled trials, mHealth data and a survey of experts.

Author Contributions

Bernardo Sousa-Pinto, Jean Bousquet, Holger J. Schünemann and Torsten Zuberbier were responsible for the coordination of the project (as members of the ARIA 2024–2025 guidelines steering committee) and contributed to the methodology (including evidence synthesis and analysis), discussion of the evidence and drafting of recommendations (as members of the ARIA 2024–2025 guideline panel) and writing the manuscript. Rafael José Vieira and Antonio Bognanni contributed to the methodology (including evidence synthesis and analysis), discussion of the evidence and drafting of recommendations (as members of the ARIA 2024–2025 guideline panel) and writing the manuscript. Arunas Valiulis, Sian Williams, Anna Bedbrook, Maria Jose Torres, G Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Yuliia Palamarchuk, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila-Salmi, Maria Teresa Ventura, Juan José Yepes-Núñez, Elena Azzolini, Gilles Louis, Elena Parmelli and Jaron Zuberbier contributed to the discussion of the evidence and drafting of recommendations (as members of the ARIA 2024–2025 guideline panel) and writing the manuscript. Rita Amaral, Sara Gil-Mata, Manuel Marques-Cruz, Ewa Borowiack, Raquel Albuquerque Costa, Olga Mariana Cunha, Renato Ferreira-da-Silva, Despo Ierodiakonou, Justyna Litynska, Inês Ribeiro-Vaz, Ewelina Sadowska, Tuuli Thomander and João A. Fonseca contributed to the methodology (including evidence synthesis and analysis) and revising and editing the manuscript. All other authors were part of the international panel revising the recommendations, contributing to the guidelines by providing feedback on the recommendations and revising and editing the manuscript.

Affiliations

¹MEDCIDS—Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal | ²CINTESIS@RISE—Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal | ³Institute of Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany | ⁴Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany | ⁵ARIA (Allergic Rhinitis and Its Impact on Asthma), Montpellier, France | ⁶Department of Health Research Methods, Evidence, and Impact & Department of Medicine, McMaster University, Hamilton, Ontario, Canada | ⁷Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy | ⁸Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA | ⁹Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland | ¹⁰Institute of Clinical Medicine and Institute of Health Sciences, Medical Faculty of Vilnius University, Vilnius, Lithuania | ¹¹Clinic of Asthma, Allergy and Chronic Lung Diseases, Vilnius, Lithuania | ¹²International Primary Care Respiratory Group

IPCRG, Edinburgh, UK | ¹³Medical Consulting Czarlewski, Levallois, France | ¹⁴Allergy Unit, Málaga Regional University Hospital of Málaga, Málaga University, ARADyAL, Málaga, Spain | ¹⁵Immunomodulation and Tolerance Group and Allergy and Clinical Immunology, Imperial College London, London, UK | ¹⁶Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal | ¹⁷Asthma & Allergy Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy | ¹⁸Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain | ¹⁹Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA | ²⁰“Respiriamo Insieme” Association, Asthma & Allergy Center, Padova, Italy | ²¹Department of Otolaryngology, Head & Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany | ²²Center for Rhinology and Allergology, Allergology & Rhinology Department, Wiesbaden, Germany | ²³Department of Political Science, University of Zürich, Zürich, Switzerland | ²⁴RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal | ²⁵Finnish Meteorological Institute (FMI), Atmospheric Composition Research, Helsinki, Finland | ²⁶Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece | ²⁷PaCeIT—Patient Centered Innovation and Technologies, Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal | ²⁸Allergy Unit, Instituto and Hospital CUF, Porto, Portugal | ²⁹Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain | ³⁰Universitat Pompeu Fabra (UPF), Barcelona, Spain | ³¹CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain | ³²Department of Allergy, Skin and Allergy Hospital, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland | ³³Department of Otorhinolaryngology, University of Eastern Finland and the North Savo Wellbeing Services County, Kuopio, Finland | ³⁴University of Bari Medical School, Bari, Italy | ³⁵Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy | ³⁶School of Medicine, Universidad de los Andes, Bogotá, D. C., Colombia | ³⁷Pulmonology Service, Internal Medicine Section, Fundación Santa Fe de Bogotá, University Hospital, Bogotá, D. C., Colombia | ³⁸Fundacao ProAR and (Faculdade de Medicina da), Universidade Federal da Bahia, Salvador, Bahia, Brazil | ³⁹Casa di Cura Villa Montallegro, Allergology Department, Genova, Italy | ⁴⁰Department of Pulmonary Diseases and Institute of Pulmonology and Tuberculosis, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey | ⁴¹Department of Health Sciences, University of Florence, Florence, Italy | ⁴²Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy | ⁴³Department of Immunology and Allergology, Lithuanian University of Health Sciences, Kaunas, Lithuania | ⁴⁴Department of Pediatrics and Adolescent Medicine, University of Turku, Turku University Hospital, Turku, Finland | ⁴⁵Institute of Clinical Immunology and Medical Genetics, Department of Paediatrics and Adolescent Medicine, Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine, Martin, Slovakia | ⁴⁶Comenius University, Bratislava, Slovakia | ⁴⁷University Teaching Hospital Martin, Martin, Slovakia | ⁴⁸Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland | ⁴⁹Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania | ⁵⁰Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania | ⁵¹Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico | ⁵²Allergy & Immunology Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia | ⁵³National Center for Research in Chronic Respiratory Diseases, Collaborating With WHO—EMRO Tishreen University School of Medicine, Latakia, Syria | ⁵⁴Al-Sham Private University, Pharmacy Department, Damascus, Syria | ⁵⁵Japan Antituberculosis Association (JATA), Fukujuji Hospital, Tokyo, Japan | ⁵⁶Department of Respiratory Medicine, JSS Medical College, JSSAHER Mysuru, Mysore, Karnataka, India | ⁵⁷Departement of Biological Sciences and Pathophysiology, University of Veterinary Medicine, Vienna, Austria | ⁵⁸Section of Rhinology and Allergy, Department of

Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany | ⁵⁹Allergy and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal | ⁶⁰Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine, University of Coimbra, Coimbra, Portugal | ⁶¹Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal | ⁶²UBIAir—Clinical & Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal | ⁶³Pneumologie, AP-HP Centre Université de Paris Cité, Hôpital Cochin, Paris, France | ⁶⁴UMR 1016, Institut Cochin, Paris, France | ⁶⁵Inserm, Equipe D'épidémiologie Respiratoire Intégrative, CESP, Villejuif, France | ⁶⁶Department of Immunoallergy, Cova da Beira University Hospital Centre, Covilhã, Portugal | ⁶⁷Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Copenhagen, Denmark | ⁶⁸Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark | ⁶⁹Pediatrics, Allergy & Immunology, Latin American Society of Allergy, Asthma & Immunology (SLAAI), Montevideo, Uruguay | ⁷⁰Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy | ⁷¹Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China | ⁷²Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland | ⁷³Universidad Espíritu Santo, Samborondón, Ecuador | ⁷⁴Department of Allergology & Pulmonology, Respiralab Research Group, Guayaquil, Guayas, Ecuador | ⁷⁵Servicio de Alergia e Immunología, Clínica Santa Isabel, Buenos Aires, Argentina | ⁷⁶Global NCD Platform, Geneva, Switzerland | ⁷⁷Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey | ⁷⁸Department of Otorhinolaryngology—Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia | ⁷⁹Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait | ⁸⁰Adult Allergy and Immunology Division—Hamad Medical Corporation, Doha, Qatar | ⁸¹Department of Cardiovascular and Respiratory Sciences, Porto Health School, Polytechnic Institute of Porto, Porto, Portugal | ⁸²Department of Women's and Children's Health, Paediatric Research, Uppsala University, Uppsala, Sweden | ⁸³Department of Internal Medicine, University of Medicine, Tirana, Albania | ⁸⁴Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA | ⁸⁵Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA | ⁸⁶Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy | ⁸⁷Respiratory & Allergy Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy | ⁸⁸Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil | ⁸⁹NOVA Medical School/Comprehensive Health Research Centre (CHRC), Lisbon, Portugal | ⁹⁰Serviço de Imunoalergologia, Centro Hospitalar Universitário de Lisboa Central/ULS São José, Lisbon, Portugal | ⁹¹Division of Allergy/Immunology, University of South Florida, Tampa, Florida, USA | ⁹²SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy | ⁹³Allergy, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy | ⁹⁴Department of Internal Medicine 'A. Murri' and Unit of Geriatric Immunoallergy, University of Bari Medical School, Bari, Italy | ⁹⁵Faculty of Public Health, Sofia Medical University, Sofia, Bulgaria | ⁹⁶Latvian Association of Allergists, University Children Hospital, Riga, Latvia | ⁹⁷Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal | ⁹⁸CINTESIS@RISE, Biochemistry Lab, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto, Porto, Portugal | ⁹⁹Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital “Duiilo Casula”, University of Cagliari, Cagliari, Italy | ¹⁰⁰VIM Suresnes, UMR 0892, Pôle Des Maladies Des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France | ¹⁰¹Medical Faculty Skopje, University Clinic of Pulmology and Allergy, Skopje, Republic of North

Macedonia | ¹⁰²Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt | ¹⁰³Department of Otorhinolaryngology, Chiba University, Chiba, Japan | ¹⁰⁴Department of Internal Medicine and Infectious Diseases, St Joseph University, Hotel Dieu de France Hospital, Beirut, Lebanon | ¹⁰⁵Department of Allergology and Clinical Immunology, Kazakhstan Association of Allergology and Clinical Immunology, Kazakh National Medical University, Almaty, Kazakhstan | ¹⁰⁶Institute of Clinical Medicine, Children's Clinic, Tartu University, Tartu, Estonia | ¹⁰⁷Poltava State Medical University, Immunology & Allergology Department, Poltava, Ukraine | ¹⁰⁸Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh | ¹⁰⁹Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary | ¹¹⁰Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden | ¹¹¹Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden | ¹¹²Department of Pediatric Respiratory Diseases and Allergology, Medical University of Warsaw, Warsaw, Poland | ¹¹³Department of Clinical and Laboratory Immunology, Allergology and Medical Genetics, Bogomolets National Medical University, Kyiv, Ukraine | ¹¹⁴Institute of Translational Pharmacology (IFT)-National Research Council (CNR), Palermo, Italy | ¹¹⁵Croatian Pulmonary Society, Clinical Center for Pulmonary Diseases, Zagreb, Croatia | ¹¹⁶Asthma, COPD Outpatient Care Unit, University Medical Center, Hô-Chi-Minh City, Vietnam | ¹¹⁷Allergy Unit "D Kalogeromitros", 2nd Department of Dermatology and Venereology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece | ¹¹⁸Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia | ¹¹⁹Division of Respiratory Disease and Allergy, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea | ¹²⁰Department of Medicine, Faculty of Medicine and Surgery, University of Malta, Msida, Malta | ¹²¹EPIUnit-Institute of Public Health, University of Porto, and Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal | ¹²²Serviço de Imunoalergologia, Centro Hospitalar Universitário São João, Porto, Portugal | ¹²³Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal | ¹²⁴Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain | ¹²⁵Clinical & Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain | ¹²⁶Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France | ¹²⁷Imperial College Healthcare NHS Trust, London, UK | ¹²⁸University of Liverpool, Liverpool, UK | ¹²⁹Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina | ¹³⁰Department of Allergology, Medical University of Gdansk, Gdansk, Poland | ¹³¹ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo | ¹³²Allergy, Asthma and Clinical Immunology, Alfred Health and Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia | ¹³³Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland | ¹³⁴Chiba Rosai Hospital, ENT Department, Chiba, Japan | ¹³⁵Chiba University Hospital, Department of Otolaryngology, Head and Neck Surgery, Chiba, Japan | ¹³⁶Department of Otorhinolaryngology, Charité—Universitätsmedizin Berlin, Berlin, Germany | ¹³⁷Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain | ¹³⁸Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic | ¹³⁹Division of Allergy and Clinical Immunology, Department of Medicine, "Santa Maria della Speranza" Hospital, Battipaglia, Salerno, Italy | ¹⁴⁰Agency of Health ASL, Division of Allergy and Clinical Immunology, Department of Medicine, Salerno, Italy | ¹⁴¹Postgraduate Programme in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy | ¹⁴²Department of Pediatrics, Nippon Medical School, Tokyo, Japan | ¹⁴³Medical School, University of Cyprus, Nicosia,

Cyprus | ¹⁴⁴Clinic of Occupational Diseases, University Hospital Sveti Ivan Rilski, Sofia, Bulgaria | ¹⁴⁵IRCCS Humanitas Research Center, Personalized Medicine Asthma & Allergy, Rozzano, Milan, Italy | ¹⁴⁶Department of Pulmonology and Allergology, Klaipeda National Hospital, Klaipėda, Lithuania | ¹⁴⁷Vilnius University Medical Faculty, Vilnius, Lithuania | ¹⁴⁸Division of Adult and Pediatric Allergy and Immunology, University of the Philippines—Philippines General Hospital, Manila, Philippines | ¹⁴⁹Department of Allergy, Clinics Hospital, National University, San Lorenzo, Paraguay | ¹⁵⁰Faculty of Medicine, University of Southampton, Southampton, UK | ¹⁵¹The David Hide Asthma and Allergy Centre, St Mary's Hospital, Newport, Isle of Wight, UK | ¹⁵²NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK | ¹⁵³LEADER Research Inc., Hamilton, Ontario, Canada | ¹⁵⁴Division of Allergy, Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel | ¹⁵⁵Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel | ¹⁵⁶Aria, Asthma, Rhinitis, Immunology & Allergy Department, Athens, Greece | ¹⁵⁷Allergy Service, Fundacion Jimenez Diaz, Autonoma University of Madrid, CIBERES-ISCIH, Madrid, Spain | ¹⁵⁸PROMISE Department, University of Palermo, Palermo, Italy | ¹⁵⁹Allergy & Asthma, Medical Director, CLINICA SISUL, FACAIA, SPAAL, Asuncion, Paraguay | ¹⁶⁰Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil | ¹⁶¹Division of Respiratory Medicine, Department of Pediatrics, Hospital Nacional de Niños, Universidad de Costa Rica, San Jose, Costa Rica | ¹⁶²Department of Respiratory Medicine and Tuberculosis, University Hospital, Brno, Czech Republic | ¹⁶³Department of Otolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand | ¹⁶⁴Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal | ¹⁶⁵International Primary Care Respiratory Group IPCRG, Aberdeen, UK | ¹⁶⁶Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece | ¹⁶⁷Federal University of Pampa, Department of Medicine, Uruguaiana, Brazil | ¹⁶⁸Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland | ¹⁶⁹FILHA, Finnish Lung Health Association, Helsinki, Finland | ¹⁷⁰Department of Clinical Medicine, Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland | ¹⁷¹Nova Southeastern University, College of Allopathic Medicine, Fort Lauderdale, Florida, USA | ¹⁷²Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore | ¹⁷³Division of Allergy and Immunology, Department of Dermatology, Allergy and Venerology, Charité Universitätsmedizin Berlin, Berlin, Germany | ¹⁷⁴The Allergy and Asthma Institute, Allergy & Asthma Department, Islamabad, Pakistan | ¹⁷⁵University Clinic of Respiratory and Allergic Diseases, Pulmonary & Allergy Department, Golnik, Slovenia | ¹⁷⁶Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia | ¹⁷⁷Pulmonary Department, Rashid Hospital, DUBAI Health, Dubai, UAE | ¹⁷⁸Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, UAE | ¹⁷⁹Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain | ¹⁸⁰Oasi Research Institute-IRCCS, Troina, Italy | ¹⁸¹BIOS S.P.A. Società Benefit, Rome, Italy | ¹⁸²Department of Dermatology, Medical University of Graz, Graz, Austria | ¹⁸³Department of Allergy and Immunology, Para State University Center—CESUPA, Belém, Brazil | ¹⁸⁴Allergy Department, Hospital Clínic and IDIBAPS, Universitat de Barcelona, Barcelona, Spain | ¹⁸⁵RICORS de Enfermedades Inflammatorias (ISCIH), Madrid, Spain | ¹⁸⁶Department for Otorhinolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany | ¹⁸⁷Respiratory Medicine, University of Modena & Reggio Emilia, Azienda Ospedaliera-Universitaria di Modena, Modena, Italy | ¹⁸⁸Pediatric Unit, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy | ¹⁸⁹Evidence Prime, Kraków, Poland | ¹⁹⁰Evidence Prime, Hamilton, Ontario, Canada | ¹⁹¹Laval University, Quebec City, Quebec, Canada | ¹⁹²Department of Pediatric Allergology, Armand Trousseau University Hospital, Sorbonne University, AP-HP, Paris,

France | ¹⁹³French National Reference Center for Angioedema (CREAK), Saint-Antoine University Hospital, Paris, France | ¹⁹⁴CRESS, Inserm, INRAE, HERA Team, Paris Cité University, Paris, France | ¹⁹⁵Department of Medical Sciences, University of Turin, Turin, Italy | ¹⁹⁶Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy | ¹⁹⁷Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany | ¹⁹⁸Pneumology Department, Hospital Universitari Dexeus, Barcelona, Spain | ¹⁹⁹CIBER of Respiratory Diseases, Group of Rhinitis, Rhinosinusitis and Nasal Polyps, Area of Asthma, SEPAR, Barcelona, Spain | ²⁰⁰Clinique Des Bronches, Allergie et Sommeil, Hôpital Nord, Marseille, France | ²⁰¹Department of Public Health and Primary Care, Leiden University Medical Centre, Leiden, the Netherlands | ²⁰²National eHealth Living Lab, Leiden, the Netherlands | ²⁰³Department of Pulmonology and Allergology, Medical University of Gdańsk, Gdańsk, Poland | ²⁰⁴Department of Allergology and Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China | ²⁰⁵Allergist, David Tvildiani Medical University, Tbilisi, Georgia | ²⁰⁶University of South Florida, College of Medicine, Division of Allergy-Immunology, Department of Internal Medicine, Tampa, Florida, USA | ²⁰⁷Associate Professor of Pediatrics, Division of Allergy and Immunology, Federal University of Parana, Curitiba, Brazil | ²⁰⁸Paediatric Allergy Clinic, Department of Dermatology, Amersham Hospital, NHS Hospital Trust, Amersham, UK | ²⁰⁹Evidence in Allergy Group, McMaster University and the Research Institute of St. Joe's Hamilton, Hamilton, Canada | ²¹⁰Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey | ²¹¹Scientific & Medical Department, Lofarma S.p.A., Milan, Italy | ²¹²LAQV@REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal | ²¹³Woolcock Institute of Medical Research, Sydney, Australia | ²¹⁴Allergy Section, Department of Internal Medicine, Hospital Vall D'hebron, Barcelona, Spain | ²¹⁵ARADyAL Research Network, Barcelona, Spain | ²¹⁶Division of Respiratory and Allergic Diseases, High Specialty Hospital 'A Cardarelli', and Respiratory Allergy School of Specialization in Respiratory Diseases, Federico II University of Naples, Naples, Italy | ²¹⁷Centre for Immunology and Infection Control, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia | ²¹⁸Office of Research, Metro North Hospital and Health Service, Brisbane, Australia | ²¹⁹University of Foggia, Department of Medical and Surgical Science, Foggia, Italy | ²²⁰Allergy and Clinical Immunology Centro Regional, Hospital Universitario, Universidad Autónoma de Nuevo Leon, Monterrey, Mexico | ²²¹Department of Otorhinolaryngology, Head and Neck Surgery, University of Crete, School of Medicine, Heraklion, Crete, Greece | ²²²Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia in Katowice, Katowice, Poland | ²²³Pediatrics Department, Universidad Austral de Chile, Valdivia, Chile | ²²⁴Department of Pulmonary Medicine, Division of Immunology, Allergy and Asthma, Laboratory of Occupational and Environmental Respiratory Diseases, Faculty of Medicine, Ege University, EgeSAM (Ege University Translational Pulmonary Research Center), Bornova, Izmir, Türkiye | ²²⁵Faculty of Health Sciences, Catholic University of Salta, Salta, Argentina | ²²⁶Center of Allergy and Immunology, and Georgian Academy of Allergy, Asthma, and Clinical Immunology, Tbilisi, Georgia | ²²⁷Former President of the Hellenic Society of Allergology and Clinical Immunology, Department of Allergy and Clinical Immunology, Air Force General Hospital, Athens, Greece | ²²⁸Riga East University Hospital, Riga, Latvia | ²²⁹Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile | ²³⁰Quality Use of Research Medicines Group, Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia | ²³¹Macquarie University, Macquarie Park, New South Wales, Australia | ²³²Faculty of Health, University of Plymouth, Plymouth, UK | ²³³Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus | ²³⁴Otolaryngology Department, General Hospital of Kalamata, Kalamata City, Greece | ²³⁵Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton,

Ontario, Canada | ²³⁶Occupational and Environmental Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden | ²³⁷ORL SOKLIC KOSAK, Ljubljana, Slovenia | ²³⁸University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia | ²³⁹Medical Faculty, University of Ljubljana, Ljubljana, Slovenia | ²⁴⁰Bagilar Research and Training Hospital, Department of Chest Diseases, Istanbul, Turkey | ²⁴¹Clinical Management Group, Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia | ²⁴²Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia | ²⁴³Departmental Unit of Allergology, Clinical Immunology & Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy | ²⁴⁴Department of Public Health, University of Liège, Liège, Belgium | ²⁴⁵Department of Pneumology, GIGA I3 Research Group, University of Liège, Liège, Belgium | ²⁴⁶Allergy Unit, Department of Internal Medicine, University Hospital AOU Delle Marche, Ancona, Italy | ²⁴⁷Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy | ²⁴⁸Department of Otorhinolaryngology, Head and Neck Surgery, Ankara University Medical School, Ankara, Turkey | ²⁴⁹Department of Otorhinolaryngology Head and Neck Surgery, Salzburg Paracelsus Medical University, Salzburg, Austria | ²⁵⁰Department of Otolaryngology, Head and Neck Surgery, Cornell University, Weill Cornell Medical College, New York, New York, USA | ²⁵¹Allergy & Clinical Immunology Department, University Hospital Center "Mother Teresa", Tirana, Albania | ²⁵²UMF-University of Medicine and Pharmacy 'Carol Davila', Pneumology Department, National Institute of Pneumology 'Marius Nasta', Bucharest, Romania | ²⁵³Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland | ²⁵⁴Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA | ²⁵⁵Department of Environmental Health, Harvard TH Chan School of Public Health and Department of Medicine, Division of Allergy and Inflammation, Beth Israel Deaconess Hospital, Boston, Massachusetts, USA | ²⁵⁶Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg | ²⁵⁷Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark | ²⁵⁸Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland | ²⁵⁹Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea | ²⁶⁰Clinical Epidemiology and Research Center, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy | ²⁶¹Otorhinolaryngology and Neck Surgery Unit, San Juan de Dios National Hospital, San Miguel, El Salvador | ²⁶²Allergist, Private Practice, Mexico City, Mexico | ²⁶³Ecole Polytechnique de Palaiseau, Palaiseau, France | ²⁶⁴IRBA (Institut de Recherche Bio-Médicale Des Armées), Bretigny sur Orge, France | ²⁶⁵Université Paris Cité, Paris, France | ²⁶⁶Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium | ²⁶⁷Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon | ²⁶⁸Department of Otorhinolaryngology-Head and Neck Surgery, Dar Al Shifa Hospital, Salmiya, Kuwait | ²⁶⁹Center Allergy & Immunology/Geomedi Teaching University, Faculty of Medicine, Tbilisi, Georgia | ²⁷⁰Usher Institute, University of Edinburgh, Edinburgh, UK | ²⁷¹Department of Otorhinolaryngology, Yamanashi University, Yamanashi, Japan | ²⁷²Mohammed Bin Rashid University (MBRU), Dubai Health, Dubai, UAE | ²⁷³Asthma Reference Center—School of Medicine of Santa Casa de Misericórdia of Vitória, Espírito Santo, Brazil | ²⁷⁴Department of Otorhinolaryngology and Head & Neck Surgery, CHU Rangueil-Larrey, Toulouse, France | ²⁷⁵Allergy Service, University Hospital Professor Polydoro Ernani de São Thiago (HU-UFSC/EBSERH), Florianópolis, Brazil | ²⁷⁶Department of Internal Medicine, Federal University of Santa Catarina (UFSC), Florianópolis, Brazil | ²⁷⁷Otolaryngology-HNS, University of Zurich, University Hospital of Zurich, Zurich, Switzerland | ²⁷⁸Clinic of Allergology and Immunology, University Clinical Center of Serbia, Belgrade, Serbia | ²⁷⁹Faculty of Medicine, University of Belgrade, Belgrade,

Serbia | ²⁸⁰Department of Respiratory Medicine, Medical Professorial Unit, Tallaght University Hospital & Trinity College, Dublin, Ireland | ²⁸¹Dr Agostinho Neto University Hospital, Praia, Cabo Verde | ²⁸²Immunology, Cabo Verde University, Faculty of Medicine, Praia, Cabo Verde | ²⁸³The Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland | ²⁸⁴Faculty of Medicine, University of Porto, Porto, Portugal | ²⁸⁵Department of Immunology and Allergology, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic | ²⁸⁶Charles University, Prague, Czech Republic | ²⁸⁷Department of Medicine Solna, Division of Immunology and Respiratory Medicine, Karolinska Institutet, Stockholm, Sweden | ²⁸⁸Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden | ²⁸⁹Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden | ²⁹⁰Samitivej Allergy Institute, Bangkok, Thailand | ²⁹¹Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University, Faculty of Medicine, Bangkok, Thailand | ²⁹²Department of Otorhinolaryngology, Heinrich Heine University Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany | ²⁹³The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China | ²⁹⁴ENT and Allergology, Düsseldorf, Germany | ²⁹⁵Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China | ²⁹⁶The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China | ²⁹⁷Servicio de Alergia e Inmunología clínica, Hospital Universitario de Puebla, Puebla, México

Acknowledgements

Open Access funding enabled and organized by Projekt DEAL.

Disclosure

Dr. Alkis Togiás' co-authorship of this report does not constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other Agency of the United States Government.

Conflicts of Interest

J. Bousquet reports personal fees from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi-Aventis, Teva, Noucor, other from KYomed-Innov, other from Mask-air-SAS, outside the submitted work. D. Larenas Linnemann reports personal fees from ALK, Armstrong, Astrazeneca national and global, Bayer, Chiesi, Grunenthal, Grin, GSK national and global, Viatrix, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, Carnot, Syneos Health, grants from Abbvie, Bayer, Lilly, Sanofi, Astrazeneca, Pfizer, Novartis, Pulmonair, GSK, Chiesi, Biopharma, outside the submitted work; and Editor in chief of Immune System (Karger)—member of asthma committee ACAAI—subgroup chair of allergen immunotherapy Practice parameter update JTF AAAAI/ACAAI 2024—member of allergen immunotherapy committee AAAAI—chair of allergen immunotherapy committee CMICA—member of allergic asthma task force EAACI. M. Blaiss reports personal fees from Opella, personal fees from GSK, personal fees from Sanofi, personal fees from AstraZeneca, personal fees from Bayer, during the conduct of the study. M. Worm reports other from AbbVie Deutschland GmbH & Co. KG, other from Aimmune Therapeutics UK Limited, other from ALK-Abelló Arzneimittel GmbH, other from Allergopharma GmbH & Co KG, other from Almirall Hermal GmbH, other from Amgen GmbH, other from AstraZeneca GmbH, other from Bayer AG, other from Bencard Allergy GmbH, other from Bioprojet Pharma, other from Boehringer Ingelheim Pharma GmbH & Co. KG, other from Bristol Myers Squibb GmbH & Co. KGaA, other from Galderma Laboratorium GmbH, other from Glaxo Smith Kline GmbH & Co. KG, other from Infectopharm Arzneimittel und Consilium GmbH, other from LEO Pharma GmbH, other from Lilly Deutschland GmbH, other from Mylan Germany GmbH (A Viatrix Company), other from Novartis AG, other from Octapharma AG, other from Pfizer Pharma GmbH, other from Sanofi-Aventis Deutschland GmbH/

Denzyme Europe B. B.Đ, outside the submitted work. A. Boner reports that Envicon Medical SRL belongs to my son Tommaso. Envicon Medical produces a nutraceutical (Auxilie Immuplus) with antioxidant activity. P. Devillier reports personal fees and nonfinancial support from Astra Zeneca, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Menarini, personal fees from Viatrix, personal fees from Meda Pharma, personal fees from ALK-Abello, personal fees and nonfinancial support from Stallergenes, outside the submitted work. N. Papadopoulos reports personal fees from Nestlé Nutrition Institute, personal fees from Abbott Nutrition, grants from Numil Hellas SA, grants from VIANEX, personal fees from GSK, personal fees from HAL Allergy Holding B.V, personal fees from Menarini International Operations Luxembourg SA, personal fees from Regeneron Pharmaceuticals Inc., personal fees from Berlin—Chemie AG, personal fees from DBV Technologies SA, grants from Vibrant America, personal fees from Hyproca Nutrition USA INC, personal fees from Danone Trading Medical B.V., personal fees from Med Maps srl, outside the submitted work. R. Naclerio reports personal fees from Lyra, personal fees from Sanofi, outside the submitted work. S. Toppila-Salmi reports grants and other support from GSK, grants and other support from Sanofi, other support from AstraZeneca, other support from ALK-Abelló, others support from OrionPharma, outside the submitted work. J. Bernstein reports grants from Allergy Therapeutics, grants from ALK, outside the submitted work. I am also on the JTF for the AAAAI/ACAAI and co-author on the Rhinitis guidelines. Also, Chairman of the AAAAI Foundation and a member of the WAO board of directors. B. Gradauskiene reports personal fees from Viatrix, personal fees from Berlin-Chemie Menarini, grants and personal fees from AstraZeneca, personal fees from Mylan Healthcare, personal fees from AbbVie, outside the submitted work. M. Wagenmann reports personal fees from Allergopharma, personal fees from ALK-Abello, grants and personal fees from AstraZeneca, personal fees from CSL Behring, grants and personal fees from GSK, personal fees from HAL, personal fees from Leti Pharma, personal fees from MSD, personal fees from Novartis, grants and personal fees from Regeneron, grants and personal fees from Sanofi, personal fees from Stallergenes, grants from Takeda, outside the submitted work. I. Pali-Schöll reports speaker fees from Bencard GmbH. M. Kupczyk reports personal fees from Adamed, personal fees from Astra Zeneca, personal fees from Abbvie, personal fees from Chiesi, personal fees from Berlin Chemie Menarini, personal fees from Glenmark, personal fees from GSK, personal fees from Novartis, personal fees from Sanofi, personal fees from Stada, personal fees from HVD, personal fees from Emma, personal fees from Celon Pharma, personal fees from Lek-Am, personal fees from Teva, outside the submitted work. J. SASTRE reports grants and personal fees from SANOFI, personal fees from GSK, personal fees from NOVARTIS, personal fees from ASTRA ZENECA, personal fees from MUNDIPHARMA, personal fees from FAES FARMA, outside the submitted work. A. Cruz reports personal fees from AstraZeneca, personal fees from CHIESI, personal fees from GSK, personal fees from Eurofarma, personal fees from Sanofi, personal fees from Farmoquímica, personal fees from Sunvou, outside the submitted work. M. Soyka reports other from Sanofi, other from GSK, other from MSD, other from Astra Zeneca, other from Novartis, outside the submitted work. J. Mullol reports personal fees and other from SANOFI-GENZYME and REGENERON, grants, personal fees and other from VIATRIS/MEDA Pharma, grants and personal fees from NOUCOR/URIACH Group, personal fees from Menarini, personal fees from UCB, personal fees and other from AstraZeneca, grants, personal fees and other from GSK, personal fees from MSD, personal fees and other from Lilly, personal fees and other from GLENMARK, outside the submitted work. T. Casale reports grants and others from ELI LILLY, outside the submitted work. D. Ryan reports personal fees from Thermo-Fisher, personal fees from Menarini, personal fees from Viatrix, outside the submitted work. D. Sakurai reports grants and personal fees from Torii, grants and personal fees from Tanabe Mitsubishi, personal fees from Shionogi, grants and personal fees from Taiho, grants and personal fees from Kyorin, personal fees from Meiji Seika Pharma, personal fees from Thermo fisher scientific diagnostics, grants and personal fees from Tsumura, personal fees from Hisamitsu, personal fees from Novartis, personal fees from Sanofi, grants and personal

fees from Astra Zeneca, grants from Eli Lilly, outside the submitted work. C. Suppli Ulrik reports grants, personal fees and other from AstraZeneca, grants, personal fees and other from Boehringer Ingelheim, grants, personal fees and other from Sanofi Genzyme, personal fees and other from GlaxoSmithKline, personal fees from Berlin-Chemie Menarini, personal fees from Novartis, personal fees and other from Teva, personal fees from Orion Pharma, personal fees and other from TFF Pharmaceuticals, personal fees and other from Pfizer, personal fees and other from Chiesi, personal fees from Covis Pharma, personal fees from Takeda, personal fees from Hikma Pharmaceuticals, personal fees from Novo Nordisk, personal fees from Roche, other from European Respiratory Society, outside the submitted work. T. Zuberbier reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from AbbVie, personal fees from ALK-Abelló, personal fees from Almirall, personal fees from Astellas, personal fees from Bayer Health Care, personal fees from Bencard, personal fees from Berlin Chemie, personal fees from FAES Farma, personal fees from HAL Allergie GmbH, personal fees from Henkel, personal fees from Kryolan, personal fees from Leti, personal fees from L'Oreal, personal fees from Meda, personal fees from Menarini, personal fees from Merck Sharp & Dohme, personal fees from Novartis, personal fees from Nuocor, personal fees from Pfizer, personal fees from Sanofi, personal fees from Stallergenes, personal fees from Takeda, personal fees from Teva, personal fees from UCB, personal fees from Uriach, personal fees from Abivax, personal fees from Blueprint, personal fees from Celldex, personal fees from Celltrion, outside the submitted work; and Committee member, "Allergic Rhinitis and its Impact on Asthma" (ARIA), Member of the Board, German Society for Allergy and Clinical Immunology (DGAKI), Head, European Centre for Allergy Research Foundation (ECARF), President, Global Allergy and Asthma Excellence Network (GA²LEN), and Member, Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). M. Recto reports personal fees from VIATRIS, personal fees from GLENMARK, outside the submitted work. S. Williams reports grants from ALK Abello, outside the submitted work. E. Compalati reports personal fees from Lofarma spa, during the conduct of the study. J. Correia-de-Sousa reports other from Boehringer Ingelheim, personal fees and other from GSK, grants, personal fees and other from AstraZeneca, nonfinancial support and other from Bial, from Mundipharma, personal fees and other from Sanofi, from Novartis, personal fees from MSD, personal fees from Medinfar, outside the submitted work. L. Cecchi reports personal fees from Astra Zeneca, personal fees from GSK, personal fees from Novartis, personal fees from Chiesi, personal fees from Sanofi, personal fees from Menarini, personal fees from Thermofisher, personal fees from Firma, outside the submitted work. V. Cardona reports personal fees from Allergy Therapeutics, personal fees from Probelte, personal fees from Roxall, other from Thermofisher, personal fees from Viatri, personal fees from GSK, outside the submitted work. J. Davies reports grants from the Australian National Health and Medical Research Council, grants from the Australian Research Council, grants from the Australian Research Council, grants from NHMRC Clinical Trials and Cohort Studies 2023, grants from MRFF Chronic Respiratory Conditions, grants from Bayer Healthcare LLC USA, nonfinancial support from Swisens SA Switzerland, nonfinancial support from Kenelec Australia, outside the submitted work; in addition, Dr. Davies' organization QUT has a patent US PTO 14/311944 issued. P. Keith reports personal fees from ALK, personal fees from Bausch, personal fees from the Canadian Agency for Drugs and Technologies in Health, personal fees from Bayer, personal fees from GSK, personal fees from Medexus, personal fees from Novartis, personal fees from Sanofi, outside the submitted work. J. Litynska reports from the Fraunhofer Institute, during the conduct of the study. M. Makris reports personal fees from MENARINI, personal fees from ASTRA ZENECA, personal fees from GSK, personal fees from CHIESI, personal fees from Novartis, personal fees from ELPEN, outside the submitted work. G. Paoletti reports fees for speaker activities and/or advisory board participation from Lofarma, GSK, and AstraZeneca, outside the submitted work. I. Tsiligianni reports grants from Chiesi, GSK Hellas, Menarini, Astra Zeneca Greece, outside the submitted work. T. Haahtela reports personal fees from Orion Pharma, personal fees from ALK Nordic, outside the submitted work. H. Kraxner

reports Speaker's fee and congress support from Sanofi—Speaker's fee and congress support from Viatri—Speaker's fee and congress support from Berlin-Chemie—Speaker's fee and congress support from Ewopharma—Advisory Board membership: Sanofi—Advisory Board membership: Berlin-Chemie. M. Hyland reports a grant from GSK, grants from AstraZeneca, from null, outside the submitted work. I. Ansotegui reports personal fees from Bayer, personal fees from Eurodrug, personal fees from Gebro, personal fees from Menarini, personal fees from MSD, personal fees from Roxall, personal fees from Sanofi, personal fees from Cipla, personal fees from Glenmark, personal fees from Opella, personal fees from GSK, outside the submitted work. P. Werminghaus reports personal fees from Astrazeneca, personal fees from Bencard Allergy, personal fees from Glaxosmithkline, personal fees from Sanofi, personal fees from Stallergenes, outside the submitted work. H. Olze reports personal fees from F. Hoffmann-La Roche Ltd., Sanofi-Aventis Deutschland GmbH, AstraZeneca GmbH, GlaxoSmithKline GmbH and Co., KG, Novartis, outside the submitted work. A. Todo-Bom reports personal fees from GSK, personal fees from AstraZeneca, personal fees from Leti, personal fees from Almirall, grants from Abbvie, outside the submitted work. O. Palomares reports research grants from MINECO, Ministerio de Ciencia e Innovación, CAM, Inmunotek S.L., Novartis, and AstraZeneca and fees for giving scientific lectures or participation in Advisory Boards from AstraZeneca, Pfizer, GlaxoSmithKline, Inmunotek S.L., Novartis, Regeneron and Sanofi. R. Buhl reports personal fees from AstraZeneca, Berlin-Chemie, Celltrion, Chiesi, Cipla, Sanofi, and Teva, as well as grants to Mainz University Hospital and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche, outside the submitted work. Y. Okamoto reports personal fees from Torii Pharmaceutical Co. Ltd, personal fees from Tanabe-Mitsubishi Pharmaceutical Co. Ltd., personal fees from Kirin Holdings Co. Ltd., personal fees from Shionogi Co. Ltd., personal fees from Stallergenes-Greer, personal fees from Diichi-Sankyo, outside the submitted work. M. Giovannini reports personal fees from Sanofi, Thermo Fisher Scientific, outside the submitted work. N. Roche reports grants and personal fees from GSK, personal fees from AstraZeneca, grants and personal fees from Chiesi, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Zambon, personal fees from MSD, personal fees from Austral, personal fees from Biosency, outside the submitted work. L. Taborda-Barata reports personal fees from Sanofi, personal fees from LETI, outside the submitted work. P. Kuna reports personal fees from Adamed, personal fees from Angellini, personal fees and nonfinancial support from AstraZeneca, personal fees from Berlin Chemie Menarini, personal fees from Celon Pharma, personal fees from Chiesi, personal fees from Glenmark, personal fees from GSK, personal fees from Polpharma, personal fees from Sanofi, personal fees from Teva, personal fees from Zentiva, outside the submitted work. F. Serpa reports personal fees from Astra Zeneca, personal fees from Sanofi, personal fees from Takeda, personal fees from CSL, personal fees from Novartis, outside the submitted work. M. Ollert reports personal fees from Allergy Therapeutics, personal fees from Thermo Fisher, personal fees from Hycor Diagnostics, outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Laboratorios LETI/LETI Pharma, grants and personal fees from GlaxoSmithKline, personal fees from ROXALL Medizin, personal fees from Novartis, grants and personal fees from Sanofi-Aventis and Sanofi-Genzyme, personal fees from Med Update Europe GmbH, personal fees from streamedup! GmbH, personal fees from Pohl-Boskamp, grants from Inmunotek S.L., personal fees from John Wiley and Sons, AS, personal fees from Paul-Martini-Stiftung (PMS), personal fees from Regeneron Pharmaceuticals Inc., personal fees from RG Aertzefortbildung, personal fees from Institut für Disease Management, personal fees from Springer GmbH, grants and personal fees from AstraZeneca, personal fees from IQVIA Commercial, personal fees from Ingress Health, personal fees from Wort&Bild Verlag, personal fees from Verlag ME, personal fees from Procter&Gamble, personal fees from ALTAMIRA, personal fees from Meinhardt Congress

GmbH, personal fees from Deutsche Forschungsgemeinschaft, personal fees from Thieme, grants from Deutsche AllergieLiga e.V., personal fees from AeDA, personal fees from Alfried-Krupp Krankenhaus, personal fees from Red Maple Trials Inc., personal fees from Königlich Dänisches Generalkonsulat, personal fees from Medizinische Hochschule Hannover, personal fees from ECM Expro&Conference Management, personal fees from Technical University Dresden, grants and personal fees from Lilly, personal fees from Japanese Society of Allergy, personal fees from Forum für Medizinische Fortbildung, personal fees from Dustri-Verlag, personal fees from Pneumolive, grants and personal fees from ASIT Biotech, personal fees from LOFARMA, personal fees from Paul-Ehrlich-Institut, personal fees from Almirall, outside the submitted work; and Vice President and member of EAACI Excom, member of ext. board of directors DGAKI; coordinator, main- or co-author of different position papers and guidelines in rhinology, allergology and allergen-immunotherapy; Editor-in-Chief (EIC) of Clinical Translational Allergy (CTA), Associate Editor (AE) of Allergy. M. Moniuszko reports having received in the past personal fees and other from Berlin-Chemie/Menarini, personal fees and other from Astra Zeneca, personal fees and other from GlaxoSmithKline, personal fees and other from Novartis, personal fees and other from Chiesi, personal fees and other from Celon Pharma, personal fees and other from Takeda, personal fees and other from Polfarmex, personal fees and other from CSL Behring, personal fees from Glenmark Pharmaceuticals, personal fees and other from Sanofi, personal fees and other from Teva, outside the submitted work. T. Thomander has received personal research grants from the Finnish ORL-HNS Foundation, the Research Foundation of the Pulmonary Diseases, the Maud Kuistila Memorial Foundation, and the Foundation of the Finnish Anti-Tuberculosis Association, supporting the work on this study. The funding bodies had no role in study design, data collection, analysis, interpretation, or manuscript preparation. S. Del Giacco reports grants and personal fees from AstraZeneca, grants and personal fees from GSK, grants and personal fees from Sanofi, personal fees from Chiesi, and personal fees from Menarini, outside the submitted work. M. Bourgoïn-Heck reports non-financial support from Thermofisher, personal fees from ALK, personal fees from Takeda, personal fees from Biocryst, personal fees from DBV, outside the submitted work. H. Schünemann reports developed guidelines on Allergic Rhinitis in Asthma (ARIA) and his academic institution received research funding for it. The other authors have nothing to declare outside the submitted work.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. J. Bousquet, J. M. Anto, C. Bachert, et al., "Allergic Rhinitis," *Nature Reviews Disease Primers* 6, no. 1 (2020): 95, <https://doi.org/10.1038/s41572-020-00227-0>.
2. M. Savoure, J. Bousquet, J. J. K. Jaakkola, M. S. Jaakkola, B. Jacquemin, and R. Nadif, "Worldwide Prevalence of Rhinitis in Adults: A Review of Definitions and Temporal Evolution," *Clinical and Translational Allergy* 12, no. 3 (2022): e12130, <https://doi.org/10.1002/ct2.12130>.
3. R. J. Vieira, L. F. Azevedo, A. M. Pereira, et al., "Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-Air Study," *Journal of Allergy and Clinical Immunology: In Practice* 12, no. 11 (2024): 3107–3115.e13, <https://doi.org/10.1016/j.jaip.2024.07.026>.
4. R. J. Vieira, L. Leemann, A. Briggs, et al., "Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-Air Study," *Journal of Allergy and Clinical Immunology: In Practice* 12, no. 6 (2024): 1530–1538.e6, <https://doi.org/10.1016/j.jaip.2024.03.036>.
5. R. J. Vieira, N. Pham-Thi, J. M. Anto, et al., "Academic Productivity of Young People With Allergic Rhinitis: A MASK-Air Study," *Journal of Allergy and Clinical Immunology: In Practice* 10, no. 11 (2022): 3008–3017.e4, <https://doi.org/10.1016/j.jaip.2022.08.015>.
6. J. Bousquet, P. Van Cauwenberge, N. Khaltaev, and Aria Workshop Group; World Health Organization, "Allergic Rhinitis and Its Impact on Asthma," *Journal of Allergy and Clinical Immunology* 108, no. 5 Suppl (2001): S147–S334, <https://doi.org/10.1067/mai.2001.118891>.
7. J. Bousquet, N. Khaltaev, A. A. Cruz, et al., "Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update (In Collaboration With the World Health Organization, GA(2)LEN and AllerGen)," *Allergy* 63, no. Suppl 86 (2008): 8–160, <https://doi.org/10.1111/j.1398-9995.2007.01620.x>.
8. J. L. Brozek, J. Bousquet, C. E. Baena-Cagnani, et al., "Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines: 2010 Revision," *Journal of Allergy and Clinical Immunology* 126, no. 3 (2010): 466–476, <https://doi.org/10.1016/j.jaci.2010.06.047>.
9. J. L. Brozek, J. Bousquet, I. Agache, et al., "Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines-2016 Revision," *Journal of Allergy and Clinical Immunology* 140, no. 4 (2017): 950–958, <https://doi.org/10.1016/j.jaci.2017.03.050>.
10. J. Bousquet, H. J. Schunemann, A. Togias, et al., "Next-Generation Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines for Allergic Rhinitis Based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and Real-World Evidence," *Journal of Allergy and Clinical Immunology* 145, no. 1 (2020): 70–80.e3, <https://doi.org/10.1016/j.jaci.2019.06.049>.
11. B. Sousa-Pinto, E. M. Costa, R. J. Vieira, et al., "Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-Air Study," *Clinical and Experimental Allergy* 55 (2025): 226–238, <https://doi.org/10.1111/cea.70004>.
12. B. Sousa-Pinto, A. Sa-Sousa, R. J. Vieira, et al., "Behavioural Patterns in Allergic Rhinitis Medication in Europe: A Study Using MASK-((R)) Real-World Data," *Allergy* 77, no. 9 (2022): 2699–2711, <https://doi.org/10.1111/all.15275>.
13. B. Sousa-Pinto, R. J. Vieira, A. Bognanni, et al., "Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-Air and EAACI Methodological Committee Report," *Allergy*, ahead of print, September 26, 2025, <https://doi.org/10.1111/all.70055>.
14. J. Bousquet, H. J. Schunemann, B. Sousa-Pinto, et al., "Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024)," *Journal of Allergy and Clinical Immunology: In Practice* 12, no. 10 (2024): 2648–2668.e2, <https://doi.org/10.1016/j.jaip.2024.06.040>.
15. B. Sousa-Pinto, R. J. Vieira, M. Marques-Cruz, et al., "Artificial Intelligence-Supported Development of Health Guideline Questions," *Annals of Internal Medicine* 177, no. 11 (2024): 1518–1529, <https://doi.org/10.7326/ANNALS-24-00363>.
16. G. H. Guyatt, A. D. Oxman, R. Kunz, et al., "GRADE Guidelines: 2. Framing the Question and Deciding on Important Outcomes," *Journal of Clinical Epidemiology* 64, no. 4 (2011): 395–400, <https://doi.org/10.1016/j.jclinepi.2010.09.012>.
17. GRADEpro GDT, *GRADEpro Guideline Development Tool [Software]* (McMaster University and Evidence Prime, 2024), [gradepro.org](https://www.gradepro.org).
18. P. Alonso-Coello, H. J. Schunemann, J. Moher, et al., "GRADE Evidence to Decision (EtD) Frameworks: A Systematic and Transparent Approach to Making Well Informed Healthcare Choices. 1: Introduction," *BMJ* 353 (2016): i2016, <https://doi.org/10.1136/bmj.i2016>.
19. P. Alonso-Coello, A. D. Oxman, J. Moher, et al., "GRADE Evidence to Decision (EtD) Frameworks: A Systematic and Transparent Approach to Making Well Informed Healthcare Choices. 2: Clinical Practice Guidelines," *BMJ* 353 (2016): i2089, <https://doi.org/10.1136/bmj.i2089>.

20. I. Neumann, J. M. Anto, J. Bousquet, and H. J. Schunemann, "The Impact of Climate Change on Health Needs Structured Evidence Assessment and an Evidence to Action Framework to Make Decisions: A Proposal to Adopt the GRADE Approach," *Journal of Clinical Epidemiology* 157 (2023): 146–153, <https://doi.org/10.1016/j.jclinepi.2023.01.006>.
21. R. J. Vieira, B. Sousa-Pinto, A. Herrmann, et al., "A Novel Approach to Consider Planetary Health in Guideline Development: A GRADE Approach Using the Allergic Rhinitis and Its Impact on Asthma (ARIA) 2024-2025 Guidelines as a Case-Study," *Journal of Allergy and Clinical Immunology: In Practice* 13 (2025): 2600–2607, <https://doi.org/10.1016/j.jaip.2025.04.060>.
22. B. Sousa-Pinto, R. J. Vieira, J. Brozek, et al., "Intranasal Antihistamines and Corticosteroids in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-Analysis Protocol," *BMJ Open* 13, no. 11 (2023): e076614, <https://doi.org/10.1136/bmjopen-2023-076614>.
23. B. Sousa-Pinto, R. J. Vieira, J. Brozek, et al., "Intranasal Antihistamines and Corticosteroids in Allergic Rhinitis: A Systematic Review and Meta-Analysis," *Journal of Allergy and Clinical Immunology* 154, no. 2 (2024): 340–354, <https://doi.org/10.1016/j.jaci.2024.04.016>.
24. B. Sousa-Pinto, A. Bognanni, S. Gil-Mata, et al., "Empirical Estimation of Disutilities and Decision Thresholds for Composite Endpoints," *Journal of Clinical Epidemiology* 179 (2024): 111638, <https://doi.org/10.1016/j.jclinepi.2024.111638>.
25. B. Sousa-Pinto, R. J. Vieira, A. Bognanni, et al., "Efficacy and Safety of Intranasal Medications for Allergic Rhinitis: Network Meta-Analysis," *Allergy* 80, no. 1 (2025): 94–105, <https://doi.org/10.1111/all.16384>.
26. R. J. Vieira, M. I. Torres, A. Bognanni, et al., "Protocol for the Systematic Reviews on the Desirable and Undesirable Effects of Pharmacological Treatments of Allergic Rhinitis Informing the ARIA 2024 Guidelines," *Allergol Select* 8 (2024): 270–277, <https://doi.org/10.5414/ALX02515E>.
27. S. Gil-Mata, R. J. Vieira, E. Borowiack, et al., "Intranasal Treatments for Allergic Rhinitis in Preschool- and School-Aged Children: Network Meta-Analysis," *Journal of Allergy and Clinical Immunology: In Practice* 13 (2025): 2826–2837, <https://doi.org/10.1016/j.jaip.2025.07.004>.
28. Uppsala Monitoring Centre, "About Vigibase," <https://who-umc.org/vigibase/>.
29. J. Brozek, E. Borowiack, E. Sadowska, et al., "Patients' Values and Preferences for Health States in Allergic Rhinitis-An Artificial Intelligence Supported Systematic Review," *Allergy* 79, no. 7 (2024): 1812–1830, <https://doi.org/10.1111/all.16100>.
30. World Health Organization, *WHO Model List of Essential Medicines-23rd List* (Geneva: World Health Organization, 2023).
31. T. Piggott, T. Baldeh, B. Dietl, et al., "Standardized Wording to Improve Efficiency and Clarity of GRADE EtD Frameworks in Health Guidelines," *Journal of Clinical Epidemiology* 146 (2022): 106–122, <https://doi.org/10.1016/j.jclinepi.2022.01.004>.
32. J. Rodrigues, J. V. Pinto, P. L. Alexandre, et al., "Allergic Rhinitis Seasonality, Severity, and Disease Control Influence Anxiety and Depression," *Laryngoscope* 133, no. 6 (2023): 1321–1327, <https://doi.org/10.1002/lary.30318>.
33. M. Savoure, J. Bousquet, B. Leynaert, et al., "Asthma Is Associated With Increased Severity and Duration of Rhinitis: A Study With the Allergic Rhinitis and Its Impact on Asthma Classes in the Constances Cohort," *Clinical and Translational Allergy* 13, no. 11 (2023): e12316, <https://doi.org/10.1002/ctt2.12316>.
34. G. Galindo Rodríguez, K. P. Chávez Jiménez, S. N. González Díaz, C. Macouzet Sánchez, and C. E. de Lira Quezada, "Association Between the Correct Use of Intranasal Aerosols and Symptom Improvement in Allergic Rhinitis," *Allergologia et Immunopathologia* 53, no. 1 (2025): 55–62.
35. V. Ganesh, A. Banigo, A. McMurran, M. Shakeel, and B. Ram, "Does Intranasal Steroid Spray Technique Affect Side Effects and Compliance? Results of a Patient Survey," *Journal of Laryngology & Otology* 131, no. 11 (2017): 991–996.
36. G. Paoletti, D. Di Bona, D. K. Chu, et al., "Allergen Immunotherapy: The Growing Role of Observational and Randomized Trial 'Real-World Evidence'," *Allergy* 76, no. 9 (2021): 2663–2672, <https://doi.org/10.1111/all.14773>.

Supporting Information

Additional supporting information can be found online in the Supporting Information section. **Appendix S1:** all70131-sup-0001-AppendixS1.DOC.